{
  "usdmVersion": "4.0",
  "generatedAt": "2026-01-22T02:23:01.121536",
  "generator": "Protocol2USDM v6.5.0",
  "study": {
    "id": "a1e86918-5b0c-42f8-9c76-981746355087",
    "instanceType": "Study",
    "versions": [
      {
        "id": "6f8dd4ac-4776-4a88-9a44-eec052c7a8be",
        "instanceType": "StudyVersion",
        "versionIdentifier": "1.0",
        "studyDesigns": [
          {
            "id": "8b4f69ab-2844-47a8-96db-2bb32e4248c0",
            "name": "Study Design",
            "rationale": "Protocol-defined study design for investigating efficacy and safety",
            "instanceType": "InterventionalStudyDesign",
            "blindingSchema": {
              "id": "ebd65211-f988-4408-b049-cc6ba43c8f3a",
              "standardCode": {
                "id": "df586cc1-127f-41cf-aeda-658d76f1d0c3",
                "code": "Open Label",
                "codeSystem": "http://www.cdisc.org",
                "codeSystemVersion": "2024-09-27",
                "decode": "Open Label",
                "instanceType": "Code"
              },
              "instanceType": "AliasCode"
            },
            "randomizationType": {
              "code": "Randomized"
            },
            "arms": [
              {
                "id": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "name": "Pembrolizumab Arm",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Pembrolizumab (MK-3475) 200 mg IV every 3-weeks (Q3W) for up to 35 administrations (approx. 2 years).",
                "type": {
                  "id": "C174266",
                  "code": "C174266",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Investigational Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "4f7fee45-5154-4057-8987-6a1667eac82a",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              },
              {
                "id": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "name": "Physicians’ Choice Arm",
                "instanceType": "StudyArm",
                "dataOriginDescription": "Collected",
                "description": "Investigator’s choice of one of three regimens: Paclitaxel (80-100 mg/m2 on Days 1, 8, 15 of 28-day cycle), Docetaxel (75 mg/m2 Q3W), or Irinotecan (180 mg/m2 Q2W).",
                "type": {
                  "id": "C174267",
                  "code": "C174267",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.12e",
                  "decode": "Active Comparator Arm",
                  "instanceType": "Code"
                },
                "dataOriginType": {
                  "id": "5de16a79-15e4-4c20-9fba-3ae7aff05eda",
                  "code": "C70793",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Collected",
                  "instanceType": "Code"
                }
              }
            ],
            "studyCohorts": [
              {
                "id": "cc2428fb-cf00-494e-91d0-19bf7397a55b",
                "name": "Global Cohort",
                "instanceType": "StudyCohort",
                "characteristic": "Approximately 600 subjects enrolled globally (including China during global enrollment period) without regard to GEP biomarker status."
              },
              {
                "id": "9851a923-aa20-4d6c-ac8d-c3388c6f6422",
                "name": "China Cohort",
                "instanceType": "StudyCohort",
                "characteristic": "Approximately 120 Chinese subjects enrolled to meet local regulatory needs, including those from the China extension enrollment period."
              }
            ],
            "studyCells": [
              {
                "id": "1c41e4b6-e57a-4fdd-a703-964dc474dfae",
                "armId": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f",
                "elementIds": [
                  "29cc2364-baa2-4645-aa72-cbac39d9f8a2"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "a6cdd4a9-6b7c-4bec-9d4d-d0c3a5762d2e",
                "armId": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "elementIds": [
                  "6d0b1c0a-5206-493a-a498-2b6e70ceeca8"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "9ca74461-b407-496c-8a6d-30cf64b83946",
                "armId": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1",
                "elementIds": [
                  "5634e876-c016-43a9-931f-948af6fe3112"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "c654324c-a332-4dda-8a7a-3ac37aa5edff",
                "armId": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "elementIds": [
                  "c0dc9b11-116d-48e1-a339-27ae9d9ad1fb"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "f79c6cb3-c97a-482a-94d3-bd01dc3dd42b",
                "armId": "5f6e8c6f-ee49-40fa-a279-57bbf1218b1d",
                "epochId": "ee48e049-78eb-4490-8cde-2ded4c111306",
                "elementIds": [
                  "1abad6aa-1f8c-4cf5-8767-46c6162464b2"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "a33e5b7c-b72b-4ec7-9c3e-9d3ef0ea6e3d",
                "armId": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f",
                "elementIds": [
                  "7229b148-7309-44ee-bb84-53ebd62284cb"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "d5b6a2dc-d8a5-4078-a541-5ff68684ecf4",
                "armId": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "elementIds": [
                  "3c98f2d1-a407-474e-943b-2dc405bd5009"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "3b1e4947-da83-4cd9-8086-cd736aedc6af",
                "armId": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1",
                "elementIds": [
                  "08e10bbf-01ba-4af8-87b4-587f48b89591"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "b5c481f7-c00f-45ba-bdf1-afebc9de0202",
                "armId": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "elementIds": [
                  "778b04e9-72a2-4c9f-98d5-a5d7c67a2f6d"
                ],
                "instanceType": "StudyCell"
              },
              {
                "id": "cb6e624c-78ea-4202-a5fd-2ee9d3e65a44",
                "armId": "fee2d0af-bf9d-4958-a16f-328fa65232de",
                "epochId": "ee48e049-78eb-4490-8cde-2ded4c111306",
                "elementIds": [
                  "f4549588-9c3e-433a-bb16-876a9a73a18b"
                ],
                "instanceType": "StudyCell"
              }
            ],
            "studyElements": [
              {
                "id": "29cc2364-baa2-4645-aa72-cbac39d9f8a2",
                "name": "Pembrolizumab Arm - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Pembrolizumab Arm during Screening"
              },
              {
                "id": "6d0b1c0a-5206-493a-a498-2b6e70ceeca8",
                "name": "Pembrolizumab Arm - Initial Treatment Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Pembrolizumab Arm during Initial Treatment Phase"
              },
              {
                "id": "5634e876-c016-43a9-931f-948af6fe3112",
                "name": "Pembrolizumab Arm - Second Course Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Pembrolizumab Arm during Second Course Phase"
              },
              {
                "id": "c0dc9b11-116d-48e1-a339-27ae9d9ad1fb",
                "name": "Pembrolizumab Arm - Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Pembrolizumab Arm during Safety Follow-up"
              },
              {
                "id": "1abad6aa-1f8c-4cf5-8767-46c6162464b2",
                "name": "Pembrolizumab Arm - Survival Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Pembrolizumab Arm during Survival Follow-up"
              },
              {
                "id": "7229b148-7309-44ee-bb84-53ebd62284cb",
                "name": "Physicians’ Choice Arm - Screening",
                "instanceType": "StudyElement",
                "description": "Treatment period for Physicians’ Choice Arm during Screening"
              },
              {
                "id": "3c98f2d1-a407-474e-943b-2dc405bd5009",
                "name": "Physicians’ Choice Arm - Initial Treatment Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Physicians’ Choice Arm during Initial Treatment Phase"
              },
              {
                "id": "08e10bbf-01ba-4af8-87b4-587f48b89591",
                "name": "Physicians’ Choice Arm - Second Course Phase",
                "instanceType": "StudyElement",
                "description": "Treatment period for Physicians’ Choice Arm during Second Course Phase"
              },
              {
                "id": "778b04e9-72a2-4c9f-98d5-a5d7c67a2f6d",
                "name": "Physicians’ Choice Arm - Safety Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Physicians’ Choice Arm during Safety Follow-up"
              },
              {
                "id": "f4549588-9c3e-433a-bb16-876a9a73a18b",
                "name": "Physicians’ Choice Arm - Survival Follow-up",
                "instanceType": "StudyElement",
                "description": "Treatment period for Physicians’ Choice Arm during Survival Follow-up"
              }
            ],
            "maskingRoles": [
              {
                "id": "6baf0294-0ca2-46df-8f27-cfd8a3403085",
                "text": "This is an Open Label study with no masking",
                "isMasked": false,
                "instanceType": "Masking"
              }
            ],
            "eligibilityCriteria": [
              {
                "id": "1320436c-615c-4d99-87bf-c068246bcfbf",
                "identifier": "1",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b69dfbfb-c942-411c-8925-0a72791b4a28",
                "instanceType": "EligibilityCriterion",
                "name": "Informed Consent",
                "nextId": "70aa5fd1-a422-42c6-8295-006506e7ed2e"
              },
              {
                "id": "70aa5fd1-a422-42c6-8295-006506e7ed2e",
                "identifier": "2",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "4d406544-d47b-46fb-b8c2-b8592673d506",
                "instanceType": "EligibilityCriterion",
                "name": "Age Requirement",
                "previousId": "1320436c-615c-4d99-87bf-c068246bcfbf",
                "nextId": "c256b53d-1064-412a-90e9-985f24d4c610"
              },
              {
                "id": "c256b53d-1064-412a-90e9-985f24d4c610",
                "identifier": "3",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ef00e6f2-abc8-4d49-a28d-f8a3a0fdad52",
                "instanceType": "EligibilityCriterion",
                "name": "Diagnosis Confirmation",
                "previousId": "70aa5fd1-a422-42c6-8295-006506e7ed2e",
                "nextId": "c2c71d67-948c-4879-9cfb-60b7290b284e"
              },
              {
                "id": "c2c71d67-948c-4879-9cfb-60b7290b284e",
                "identifier": "4",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "05984ec7-36d9-4d1e-ae0c-b8a36ca31fef",
                "instanceType": "EligibilityCriterion",
                "name": "Disease Status",
                "previousId": "c256b53d-1064-412a-90e9-985f24d4c610",
                "nextId": "b3e5d90b-2dde-4401-953e-69174369a088"
              },
              {
                "id": "b3e5d90b-2dde-4401-953e-69174369a088",
                "identifier": "5",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fe64a7ad-fdc7-4de2-9028-50f86cd840aa",
                "instanceType": "EligibilityCriterion",
                "name": "Life Expectancy",
                "previousId": "c2c71d67-948c-4879-9cfb-60b7290b284e",
                "nextId": "ea3a2ae1-6d38-41ef-886c-46a4268e8344"
              },
              {
                "id": "ea3a2ae1-6d38-41ef-886c-46a4268e8344",
                "identifier": "6",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c201aea3-0569-4948-ba22-420b0a69414d",
                "instanceType": "EligibilityCriterion",
                "name": "Measurable Disease",
                "previousId": "b3e5d90b-2dde-4401-953e-69174369a088",
                "nextId": "54fb5379-a845-4306-bc16-cc953adbc412"
              },
              {
                "id": "54fb5379-a845-4306-bc16-cc953adbc412",
                "identifier": "7",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "a29b183b-2fd1-4ed4-81a9-0f4c6060abd5",
                "instanceType": "EligibilityCriterion",
                "name": "Performance Status",
                "previousId": "ea3a2ae1-6d38-41ef-886c-46a4268e8344",
                "nextId": "88522a24-5e86-44d0-b5e5-863bfea2916a"
              },
              {
                "id": "88522a24-5e86-44d0-b5e5-863bfea2916a",
                "identifier": "8",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "e91b772c-7c54-402c-a118-a74ef6ed30c0",
                "instanceType": "EligibilityCriterion",
                "name": "Prior Therapy Progression",
                "previousId": "54fb5379-a845-4306-bc16-cc953adbc412",
                "nextId": "26c8f3d6-9ca4-4e65-bd2b-36cd09d3d458"
              },
              {
                "id": "26c8f3d6-9ca4-4e65-bd2b-36cd09d3d458",
                "identifier": "9",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "331e59d6-8564-430c-b47c-f423753631ba",
                "instanceType": "EligibilityCriterion",
                "name": "Tissue Sample Provision",
                "previousId": "88522a24-5e86-44d0-b5e5-863bfea2916a",
                "nextId": "89b2d782-49f3-4c62-b8b0-bc3438e5bc76"
              },
              {
                "id": "89b2d782-49f3-4c62-b8b0-bc3438e5bc76",
                "identifier": "10",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1600fe27-e11e-45a1-ba13-e02535c81294",
                "instanceType": "EligibilityCriterion",
                "name": "Organ Function",
                "previousId": "26c8f3d6-9ca4-4e65-bd2b-36cd09d3d458",
                "nextId": "60043108-6658-45a8-87fa-a30f267f27a7"
              },
              {
                "id": "60043108-6658-45a8-87fa-a30f267f27a7",
                "identifier": "11",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "06eca800-b75a-4035-90fe-461be0a641c2",
                "instanceType": "EligibilityCriterion",
                "name": "Pregnancy Test",
                "previousId": "89b2d782-49f3-4c62-b8b0-bc3438e5bc76",
                "nextId": "d31d10a9-70de-47e1-b4a5-39901a6954ca"
              },
              {
                "id": "d31d10a9-70de-47e1-b4a5-39901a6954ca",
                "identifier": "12",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ad38ce06-a8cc-484f-a36a-f7553779e2e0",
                "instanceType": "EligibilityCriterion",
                "name": "Female Contraception",
                "previousId": "60043108-6658-45a8-87fa-a30f267f27a7",
                "nextId": "9f1211d3-6a3b-4acc-8947-9fa5967e5566"
              },
              {
                "id": "9f1211d3-6a3b-4acc-8947-9fa5967e5566",
                "identifier": "13",
                "category": {
                  "id": "C25532",
                  "code": "C25532",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Inclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1ea92e67-4207-46b5-968a-872acf05077b",
                "instanceType": "EligibilityCriterion",
                "name": "Male Contraception",
                "previousId": "d31d10a9-70de-47e1-b4a5-39901a6954ca"
              },
              {
                "id": "1282601e-5fc6-4a09-a2eb-2af2a1f5e927",
                "identifier": "E1",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0599b36d-c3d0-4ebd-8856-6909f0e4ecb8",
                "instanceType": "EligibilityCriterion",
                "name": "Investigational Agent Exclusion",
                "nextId": "3115e837-d1a8-41da-b41c-9e15c24cc367"
              },
              {
                "id": "3115e837-d1a8-41da-b41c-9e15c24cc367",
                "identifier": "E2",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "1daebf18-56bd-4aa8-89a4-eff0509f46a7",
                "instanceType": "EligibilityCriterion",
                "name": "Autoimmune Disease",
                "previousId": "1282601e-5fc6-4a09-a2eb-2af2a1f5e927",
                "nextId": "4c1cb608-ca4e-42de-84f9-199a527fee87"
              },
              {
                "id": "4c1cb608-ca4e-42de-84f9-199a527fee87",
                "identifier": "E3",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "d11a0271-772d-4654-a715-8b11fab9e21e",
                "instanceType": "EligibilityCriterion",
                "name": "Immunodeficiency/Steroids",
                "previousId": "3115e837-d1a8-41da-b41c-9e15c24cc367",
                "nextId": "1b85bcdf-823f-4e8c-84ce-293c351c410a"
              },
              {
                "id": "1b85bcdf-823f-4e8c-84ce-293c351c410a",
                "identifier": "E4",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0e08505b-429e-462a-9ed8-8140e728e69d",
                "instanceType": "EligibilityCriterion",
                "name": "CNS Metastases",
                "previousId": "4c1cb608-ca4e-42de-84f9-199a527fee87",
                "nextId": "5b5842f5-3e9f-49eb-aa33-27302718d680"
              },
              {
                "id": "5b5842f5-3e9f-49eb-aa33-27302718d680",
                "identifier": "E5",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c5aaea64-0d68-45a9-b265-ff7724be56a6",
                "instanceType": "EligibilityCriterion",
                "name": "Recent Anti-cancer Therapy",
                "previousId": "1b85bcdf-823f-4e8c-84ce-293c351c410a",
                "nextId": "94854368-73b8-4360-b904-bbbd5d214d7c"
              },
              {
                "id": "94854368-73b8-4360-b904-bbbd5d214d7c",
                "identifier": "E6",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "de09bbcc-f98e-48a2-8d0c-49ff3e60f3b9",
                "instanceType": "EligibilityCriterion",
                "name": "Prior PD-1/PD-L1 Therapy",
                "previousId": "5b5842f5-3e9f-49eb-aa33-27302718d680",
                "nextId": "d3fd6f51-d1d0-4ca7-9b78-44d4a8073ac5"
              },
              {
                "id": "d3fd6f51-d1d0-4ca7-9b78-44d4a8073ac5",
                "identifier": "E7",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "fc3b5003-8863-46e5-982e-689bb37dffcb",
                "instanceType": "EligibilityCriterion",
                "name": "mAb Hypersensitivity",
                "previousId": "94854368-73b8-4360-b904-bbbd5d214d7c",
                "nextId": "b47d81d8-8ff4-4013-9181-7ffb2622fe83"
              },
              {
                "id": "b47d81d8-8ff4-4013-9181-7ffb2622fe83",
                "identifier": "E8",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "3d536b59-2489-4086-a96e-12bd8f71df9c",
                "instanceType": "EligibilityCriterion",
                "name": "Multiple Lines of Therapy",
                "previousId": "d3fd6f51-d1d0-4ca7-9b78-44d4a8073ac5",
                "nextId": "12502af1-16f5-4010-9c2d-b40009f3ebc4"
              },
              {
                "id": "12502af1-16f5-4010-9c2d-b40009f3ebc4",
                "identifier": "E9",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "732c6a75-41a1-4de9-be60-5ede44c7f635",
                "instanceType": "EligibilityCriterion",
                "name": "Additional Malignancy",
                "previousId": "b47d81d8-8ff4-4013-9181-7ffb2622fe83",
                "nextId": "7ecfdbab-e686-4fbc-af86-81eb40aa2461"
              },
              {
                "id": "7ecfdbab-e686-4fbc-af86-81eb40aa2461",
                "identifier": "E10",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "c9c3f8c1-54dc-4a21-b069-2197baa5350b",
                "instanceType": "EligibilityCriterion",
                "name": "Live Vaccine",
                "previousId": "12502af1-16f5-4010-9c2d-b40009f3ebc4",
                "nextId": "4835257b-a606-4373-b22a-574f8a6562e5"
              },
              {
                "id": "4835257b-a606-4373-b22a-574f8a6562e5",
                "identifier": "E11",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b154f2be-ca3c-45e1-b2de-f020622f1890",
                "instanceType": "EligibilityCriterion",
                "name": "Confounding Conditions",
                "previousId": "7ecfdbab-e686-4fbc-af86-81eb40aa2461",
                "nextId": "9fe4dece-e70b-42ea-adbc-95d96db7f885"
              },
              {
                "id": "9fe4dece-e70b-42ea-adbc-95d96db7f885",
                "identifier": "E12",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "0d37e70c-a006-4322-a3b7-f4127f663ca0",
                "instanceType": "EligibilityCriterion",
                "name": "HIV History",
                "previousId": "4835257b-a606-4373-b22a-574f8a6562e5",
                "nextId": "0cfde151-5e4b-4417-afb0-a98eeb3341d3"
              },
              {
                "id": "0cfde151-5e4b-4417-afb0-a98eeb3341d3",
                "identifier": "E13",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "ec067cef-cffe-41e4-9a86-7518e8fc4eaf",
                "instanceType": "EligibilityCriterion",
                "name": "Hepatitis History",
                "previousId": "9fe4dece-e70b-42ea-adbc-95d96db7f885",
                "nextId": "2715c29e-3c08-443c-9346-b2f3f847ea7b"
              },
              {
                "id": "2715c29e-3c08-443c-9346-b2f3f847ea7b",
                "identifier": "E14",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "074d29bf-8288-45ba-a8f9-1868cdf15c46",
                "instanceType": "EligibilityCriterion",
                "name": "Pneumonitis History",
                "previousId": "0cfde151-5e4b-4417-afb0-a98eeb3341d3",
                "nextId": "5b45b058-5828-42e4-b620-cd4f0e235b15"
              },
              {
                "id": "5b45b058-5828-42e4-b620-cd4f0e235b15",
                "identifier": "E15",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "b2f2998c-9821-4097-97f2-8b1eb3a90f1d",
                "instanceType": "EligibilityCriterion",
                "name": "Active Infection",
                "previousId": "2715c29e-3c08-443c-9346-b2f3f847ea7b",
                "nextId": "5f41f8c9-4efc-4cec-a1af-746418988ce5"
              },
              {
                "id": "5f41f8c9-4efc-4cec-a1af-746418988ce5",
                "identifier": "E16",
                "category": {
                  "id": "C25370",
                  "code": "C25370",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exclusion Criteria",
                  "instanceType": "Code"
                },
                "criterionItemId": "cff187a9-4266-4259-af70-5808b8bf673f",
                "instanceType": "EligibilityCriterion",
                "name": "Psychiatric/Substance Abuse",
                "previousId": "5b45b058-5828-42e4-b620-cd4f0e235b15"
              }
            ],
            "population": {
              "id": "909cbd6d-f210-4010-9904-382d57fb5972",
              "name": "Study Population",
              "includesHealthySubjects": false,
              "criterionIds": [
                "1320436c-615c-4d99-87bf-c068246bcfbf",
                "70aa5fd1-a422-42c6-8295-006506e7ed2e",
                "c256b53d-1064-412a-90e9-985f24d4c610",
                "c2c71d67-948c-4879-9cfb-60b7290b284e",
                "b3e5d90b-2dde-4401-953e-69174369a088",
                "ea3a2ae1-6d38-41ef-886c-46a4268e8344",
                "54fb5379-a845-4306-bc16-cc953adbc412",
                "88522a24-5e86-44d0-b5e5-863bfea2916a",
                "26c8f3d6-9ca4-4e65-bd2b-36cd09d3d458",
                "89b2d782-49f3-4c62-b8b0-bc3438e5bc76",
                "60043108-6658-45a8-87fa-a30f267f27a7",
                "d31d10a9-70de-47e1-b4a5-39901a6954ca",
                "9f1211d3-6a3b-4acc-8947-9fa5967e5566",
                "1282601e-5fc6-4a09-a2eb-2af2a1f5e927",
                "3115e837-d1a8-41da-b41c-9e15c24cc367",
                "4c1cb608-ca4e-42de-84f9-199a527fee87",
                "1b85bcdf-823f-4e8c-84ce-293c351c410a",
                "5b5842f5-3e9f-49eb-aa33-27302718d680",
                "94854368-73b8-4360-b904-bbbd5d214d7c",
                "d3fd6f51-d1d0-4ca7-9b78-44d4a8073ac5",
                "b47d81d8-8ff4-4013-9181-7ffb2622fe83",
                "12502af1-16f5-4010-9c2d-b40009f3ebc4",
                "7ecfdbab-e686-4fbc-af86-81eb40aa2461",
                "4835257b-a606-4373-b22a-574f8a6562e5",
                "9fe4dece-e70b-42ea-adbc-95d96db7f885",
                "0cfde151-5e4b-4417-afb0-a98eeb3341d3",
                "2715c29e-3c08-443c-9346-b2f3f847ea7b",
                "5b45b058-5828-42e4-b620-cd4f0e235b15",
                "5f41f8c9-4efc-4cec-a1af-746418988ce5"
              ],
              "instanceType": "StudyDesignPopulation",
              "description": "Target population defined by eligibility criteria"
            },
            "objectives": [
              {
                "id": "eeaacda3-f450-4472-8c0b-ad180a30bc95",
                "name": "Primary Objective 1",
                "text": "to compare OS in subjects with squamous cell carcinoma of the esophagus.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b04cb60b-7603-49c2-b87c-bbf64d4916d6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "145beae1-aaf7-45eb-a94a-ab938a0b8190",
                "name": "Primary Objective 2",
                "text": "To compare OS in subjects with PD-L1 Combined Positive Score (CPS)≥10.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b04cb60b-7603-49c2-b87c-bbf64d4916d6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "ec724dbf-e011-4189-b1b2-c2292da518a3",
                "name": "Primary Objective 3",
                "text": "To compare OS in all subjects.",
                "level": {
                  "id": "C85826",
                  "code": "C85826",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Primary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b04cb60b-7603-49c2-b87c-bbf64d4916d6"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "901248cf-1c4b-4a6d-907a-a17a03e6eede",
                "name": "Secondary Objective 1",
                "text": "To evaluate the progression free survival (PFS) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "74d8e4aa-546b-42e5-bac7-025fa75cb920"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "248a3dfb-5f83-4482-91f2-68f4b2a3852c",
                "name": "Secondary Objective 2",
                "text": "To evaluate the Objective Response Rate (ORR) per RECIST 1.1 assessed by central vendor review in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "a836308e-c6d9-4a33-bb01-a9acfb0a27ea"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "5a2a3576-8da1-4fa0-b553-2f23af4f1b8c",
                "name": "Secondary Objective 3",
                "text": "To evaluate the PFS and ORR per RECIST 1.1 assessed by central vendor review in subjects with squamous cell carcinoma of the esophagus and subjects with PD-L1 CPS≥10, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "74d8e4aa-546b-42e5-bac7-025fa75cb920",
                  "a836308e-c6d9-4a33-bb01-a9acfb0a27ea"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "b7d6ee66-36f7-4a68-aa15-639f65c323bb",
                "name": "Secondary Objective 4",
                "text": "Evaluate the safety and tolerability profile of pembrolizumab in all subjects, when treated with pembrolizumab compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C85827",
                  "code": "C85827",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Secondary Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "6b10b34b-053e-47ff-b6a6-02c18ea1b834"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "52cde5df-2010-453b-aa77-bdd892e6810e",
                "name": "Exploratory Objective 1",
                "text": "To evaluate PFS per irRECIST assessed by blinded central vendor review in all subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "254adf3c-243c-4221-bfcd-bccde6d9f487"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "ba6a1e73-10de-4c8c-b68a-ea2d8166ec3b",
                "name": "Exploratory Objective 2",
                "text": "To evaluate efficacy by GEP expression.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "5752b0e3-e266-47d0-8df8-6393aceddbee"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "045d7d86-f03e-4b40-9d0d-cd8e915b167e",
                "name": "Exploratory Objective 3",
                "text": "To explore the concordance of PD-L1 in archival compared to newly obtained tumor tissue.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "b03b9711-2cbf-4667-a65e-cd0ed20f5bde"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "cfafe21e-e6ba-4d26-a263-8983b6aa91cb",
                "name": "Exploratory Objective 4",
                "text": "To evaluate score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "7b1cfe2c-43b6-4ac7-8960-236f0e31b500"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "32313aba-bc62-4ac3-bae5-dc31e5dab4a8",
                "name": "Exploratory Objective 5",
                "text": "To characterize utilities using EuroQol EQ-5D among subjects when treated with pembrolizumab 200 mg Q3W compared to investigator’s choice of paclitaxel, docetaxel, or irinotecan.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "792a6a8c-8a91-4806-9ff2-0edc38ee71b3"
                ],
                "instanceType": "Objective"
              },
              {
                "id": "97a84ec4-6f6a-4199-9e49-7822979a1538",
                "name": "Exploratory Objective 6",
                "text": "To explore the relationship between genetic variation and response to the treatment administered. Variation across the human genome will be analyzed for association with clinical data collected in this study.",
                "level": {
                  "id": "C163559",
                  "code": "C163559",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Trial Exploratory Objective",
                  "instanceType": "Code"
                },
                "endpointIds": [
                  "e66b5c67-8c44-491b-9322-9cde0781bc41"
                ],
                "instanceType": "Objective"
              }
            ],
            "endpoints": [
              {
                "id": "b04cb60b-7603-49c2-b87c-bbf64d4916d6",
                "name": "Primary Efficacy Endpoint",
                "text": "Overall Survival (OS)",
                "level": {
                  "id": "C98772",
                  "code": "C98772",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Primary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "74d8e4aa-546b-42e5-bac7-025fa75cb920",
                "name": "Secondary Efficacy Endpoint - PFS",
                "text": "Progression free survival (PFS) per RECIST 1.1 as assessed by the central imaging vendor",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "a836308e-c6d9-4a33-bb01-a9acfb0a27ea",
                "name": "Secondary Efficacy Endpoint - ORR",
                "text": "Objective response rate (ORR) per RECIST 1.1 as assessed by the central imaging vendor",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "6b10b34b-053e-47ff-b6a6-02c18ea1b834",
                "name": "Safety Endpoint",
                "text": "Safety and tolerability (toxicities as defined by CTCAE version 4.0, SAEs, and ECIs)",
                "level": {
                  "id": "C98781",
                  "code": "C98781",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Secondary Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Safety"
              },
              {
                "id": "254adf3c-243c-4221-bfcd-bccde6d9f487",
                "name": "Exploratory Endpoint - irRECIST",
                "text": "PFS per irRECIST assessed by blinded central vendor review",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Efficacy"
              },
              {
                "id": "5752b0e3-e266-47d0-8df8-6393aceddbee",
                "name": "Exploratory Endpoint - GEP",
                "text": "Efficacy by GEP expression",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              },
              {
                "id": "b03b9711-2cbf-4667-a65e-cd0ed20f5bde",
                "name": "Exploratory Endpoint - PD-L1 Concordance",
                "text": "Concordance of PD-L1 in archival compared to newly obtained tumor tissue",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              },
              {
                "id": "7b1cfe2c-43b6-4ac7-8960-236f0e31b500",
                "name": "Exploratory Endpoint - QoL",
                "text": "Score change of health related quality of life using the EORTC QLQ-C30 and the EORTC QLQ-OES18 from baseline",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "792a6a8c-8a91-4806-9ff2-0edc38ee71b3",
                "name": "Exploratory Endpoint - EQ-5D",
                "text": "Utilities using EuroQol EQ-5D",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "QualityOfLife"
              },
              {
                "id": "e66b5c67-8c44-491b-9322-9cde0781bc41",
                "name": "Exploratory Endpoint - Genetic",
                "text": "Relationship between genetic variation and response to the treatment administered",
                "level": {
                  "id": "C98724",
                  "code": "C98724",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.11d",
                  "decode": "Exploratory Outcome Measure",
                  "instanceType": "Code"
                },
                "instanceType": "Endpoint",
                "purpose": "Biomarker"
              }
            ],
            "estimands": [
              {
                "id": "09909237-fe9f-4216-8efd-7dc0194a5f39",
                "name": "Primary Efficacy Estimand - OS (SCC)",
                "populationSummary": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT) Summary measure: Hazard Ratio.",
                "analysisPopulationId": "da758bbd-e517-426f-b70a-8f050959e39f",
                "variableOfInterestId": "b04cb60b-7603-49c2-b87c-bbf64d4916d6",
                "interventionIds": [
                  "d3f63933-bef6-4304-9606-bc42074a4671"
                ],
                "intercurrentEvents": [
                  {
                    "id": "2b9e71f7-3095-419a-abd7-023f6a8495bf",
                    "name": "Treatment discontinuation",
                    "text": "Subject discontinues treatment for reasons other than death",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "a7481023-2546-4070-96df-fcc6a32c7750",
                    "name": "Subsequent anti-cancer therapy",
                    "text": "Initiation of non-study cancer treatment",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
                "analysisPopulation": "Subjects with advanced/metastatic squamous cell carcinoma of the esophagus (ITT)",
                "variableOfInterest": "Overall Survival (OS)",
                "summaryMeasure": "Hazard Ratio"
              },
              {
                "id": "cd8f24a8-5cf0-499c-9056-b12823e3825f",
                "name": "Primary Efficacy Estimand - OS (PD-L1 CPS≥10)",
                "populationSummary": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10 Summary measure: Hazard Ratio.",
                "analysisPopulationId": "122d1af6-8f9a-425b-ae48-65469fee40fb",
                "variableOfInterestId": "b04cb60b-7603-49c2-b87c-bbf64d4916d6",
                "interventionIds": [
                  "613ae3e0-9d92-47d2-837c-e87a0c4c6680"
                ],
                "intercurrentEvents": [
                  {
                    "id": "2b9e71f7-3095-419a-abd7-023f6a8495bf",
                    "name": "Treatment discontinuation",
                    "text": "Subject discontinues treatment for reasons other than death",
                    "strategy": "Treatment Policy",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
                "analysisPopulation": "Subjects with PD-L1 Combined Positive Score (CPS) ≥ 10",
                "variableOfInterest": "Overall Survival (OS)",
                "summaryMeasure": "Hazard Ratio"
              },
              {
                "id": "646946d2-a1ec-4ce5-8595-13b3d39e3a5a",
                "name": "Secondary Efficacy Estimand - PFS",
                "populationSummary": "All randomized subjects (ITT) Summary measure: Hazard Ratio.",
                "analysisPopulationId": "9909fc22-dbac-466c-9ce0-7e7097f970c5",
                "variableOfInterestId": "74d8e4aa-546b-42e5-bac7-025fa75cb920",
                "interventionIds": [
                  "820bdd97-1cf7-415c-bd61-b51ffab122ee"
                ],
                "intercurrentEvents": [
                  {
                    "id": "2e281ad5-1653-4d46-83f0-fca6d9d802eb",
                    "name": "Death",
                    "text": "Death due to any cause prior to progression",
                    "strategy": "Composite",
                    "instanceType": "IntercurrentEvent"
                  },
                  {
                    "id": "db6f5db1-2f3f-458a-9279-630fb84e4759",
                    "name": "New anti-cancer therapy",
                    "text": "Initiation of new anti-cancer therapy prior to documented progression",
                    "strategy": "Hypothetical",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
                "analysisPopulation": "All randomized subjects (ITT)",
                "variableOfInterest": "Progression-free survival (PFS) per RECIST 1.1 by central vendor",
                "summaryMeasure": "Hazard Ratio"
              },
              {
                "id": "80e19466-62bc-4c69-81d7-0416120c581f",
                "name": "Safety Estimand",
                "populationSummary": "All randomized subjects who received at least one dose of study treatment Summary measure: Risk Difference / Proportion of subjects with events.",
                "analysisPopulationId": "04faa647-c2d6-4369-9d7d-7c8a155170cc",
                "variableOfInterestId": "6b10b34b-053e-47ff-b6a6-02c18ea1b834",
                "interventionIds": [
                  "d7aa9159-b6eb-4953-ada4-89fefa59f611"
                ],
                "intercurrentEvents": [
                  {
                    "id": "d3fac9a1-84fa-4c0f-ba3c-2e782bc3607f",
                    "name": "Treatment discontinuation",
                    "text": "Discontinuation of study drug",
                    "strategy": "While on Treatment",
                    "instanceType": "IntercurrentEvent"
                  }
                ],
                "instanceType": "Estimand",
                "treatment": "Pembrolizumab 200 mg Q3W vs. Investigator's choice of paclitaxel, docetaxel, or irinotecan",
                "analysisPopulation": "All randomized subjects who received at least one dose of study treatment",
                "variableOfInterest": "Safety and tolerability (CTCAE v4.0 toxicities, SAEs, ECIs)",
                "summaryMeasure": "Risk Difference / Proportion of subjects with events"
              }
            ],
            "scheduleTimelines": [
              {
                "id": "837b3bdc-637f-435d-a89d-40b0c0281770",
                "name": "Main Schedule Timeline",
                "mainTimeline": true,
                "instanceType": "ScheduleTimeline",
                "entryCondition": "Subject enrolled in study",
                "entryId": "b986c86f-3673-488e-bd9a-a770e3f62a32",
                "instances": [
                  {
                    "id": "b986c86f-3673-488e-bd9a-a770e3f62a32",
                    "activityIds": [
                      "1ad03d4c-46a5-482d-adeb-f69e64931cdb"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_1@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "0e1190c1-eaf9-470d-9e32-134f57d12506",
                    "activityIds": [
                      "07ae87b8-4509-4f42-a2bf-de69abc77d65"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_2@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "db93c5b2-fb09-49a3-ab05-4b09ff12a499",
                    "activityIds": [
                      "47096d32-fd68-4d8a-8703-bd3c0bbeb448"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_3@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "27e232ec-6a69-4b23-9834-999f1b4d5848",
                    "activityIds": [
                      "39578a9d-9d32-4cbd-8ae2-727e40d59770"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_4@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "13ed0d79-7731-40ee-9fb0-336c97a6e3e9",
                    "activityIds": [
                      "4cdd7aef-e8c2-4c17-9eb0-2435e9bdcebe"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_5@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "ed93ea3e-406a-4c81-a550-4d2fec61581f",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "5ba5d9a7-316f-4f60-bc95-dc80329d3fcc",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "06d6f5ea-1d05-4377-a524-242db27b3c80",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_3",
                    "encounterId": "4bede743-2506-4a46-b81d-593ff9a4a7e9",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "55af18e9-f5c6-4ca4-9852-72b4c8af28a3",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_4",
                    "encounterId": "81574565-1107-4e9b-b767-543a55c669e5",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "05cc08fa-0e1b-4773-9b94-2a1c6bf88c01",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "aa6512f7-84a7-45b6-97e3-46ecc0b4b23c",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_6",
                    "encounterId": "0a49e14a-da14-48a9-ba48-46ed0a926711",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "34e6994c-4b9b-4b83-8aed-1f833ca0efaa",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_7",
                    "encounterId": "5766a124-5343-48f2-8826-01a809d6bd40",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "8d83ba96-0eb6-4d43-baaf-992450faa328",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "286ef37b-5960-4c49-9394-8d598c5a4380",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_9",
                    "encounterId": "5c3dccb8-2212-4904-a653-16cd791e6600",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "49f91bf4-ae62-46fa-a699-1935851b0b32",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_10",
                    "encounterId": "e464621d-6d37-451d-9d2c-e06101543298",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "3536ef36-362f-459b-be30-8d082e6462e3",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "8e5889b7-0711-4b1a-a72a-f033fc138516",
                    "activityIds": [
                      "8bff46ca-00a4-4f28-afea-b9239dbe5da6"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_6@enc_12",
                    "encounterId": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "c02f40f5-5d14-4bd6-8e52-763d160ec89f",
                    "activityIds": [
                      "442298d8-8831-4a89-ae30-6befcf07fb98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "9d48d267-04ea-4e80-88b1-1ae7e57c5b7e",
                    "activityIds": [
                      "442298d8-8831-4a89-ae30-6befcf07fb98"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_7@enc_12",
                    "encounterId": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "7a03bfb4-ce6f-4c7b-9778-f11e1070316f",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "23622c40-2f68-4e30-9ed0-cae6109a41ba",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "846f33bc-b2a8-4bb6-9ecb-16011efc9171",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_3",
                    "encounterId": "4bede743-2506-4a46-b81d-593ff9a4a7e9",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "40b07d85-788e-41e1-8d46-b0692466fe5a",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_4",
                    "encounterId": "81574565-1107-4e9b-b767-543a55c669e5",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "c3218d35-db37-403c-911d-d71874cbce11",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "ae933745-d713-495b-b581-17f1ae04fa7e",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_6",
                    "encounterId": "0a49e14a-da14-48a9-ba48-46ed0a926711",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "45a15ae0-7c7d-4db1-a9c7-10f294f32918",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_7",
                    "encounterId": "5766a124-5343-48f2-8826-01a809d6bd40",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "310adc18-9487-435e-a353-a73bd9fa4551",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "3da2ec66-5e46-45ab-b032-de476f89dc43",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_9",
                    "encounterId": "5c3dccb8-2212-4904-a653-16cd791e6600",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "043a6087-f339-46be-9125-ad9765635258",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_10",
                    "encounterId": "e464621d-6d37-451d-9d2c-e06101543298",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "b4c99998-079d-4b88-861e-bc52ee0f6502",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "cf5fe084-c830-4113-a7a6-2bf882f3cbe3",
                    "activityIds": [
                      "d0fe77a2-87d4-4e8b-a190-70b15f1599a8"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_8@enc_12",
                    "encounterId": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "b23cbd3d-d42a-4bde-88c7-eb0fec14b195",
                    "activityIds": [
                      "bc36a2e3-d5df-465c-af90-aa67e4b2402c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "39500e52-78bf-4f88-bd3b-afc3722f67d2",
                    "activityIds": [
                      "bc36a2e3-d5df-465c-af90-aa67e4b2402c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_9@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "6b13d04d-e15f-4088-9efc-c4f355ef1f00",
                    "activityIds": [
                      "a8eb24a7-3e8c-48e0-8114-8bb13823064c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "ad01ad05-e698-4bf9-bf19-4e893d60b69b",
                    "activityIds": [
                      "a8eb24a7-3e8c-48e0-8114-8bb13823064c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "ddc26f17-1544-4f31-a527-0f6628e02edf",
                    "activityIds": [
                      "a8eb24a7-3e8c-48e0-8114-8bb13823064c"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_10@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "49d2a209-aa33-452a-875c-62e576728bc0",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "74478047-05f9-46be-8474-bb53d32f49b4",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "5d5e1030-7d03-47df-9a3f-5e2359f5c85c",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_3",
                    "encounterId": "4bede743-2506-4a46-b81d-593ff9a4a7e9",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "4b7cafd5-33ea-4781-8a9d-09361b000d8a",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_4",
                    "encounterId": "81574565-1107-4e9b-b767-543a55c669e5",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "babdf217-1e99-4464-8f77-832724d06f7c",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "57602035-f1a9-46dd-882a-50c1942d1852",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_6",
                    "encounterId": "0a49e14a-da14-48a9-ba48-46ed0a926711",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "76301628-5086-4b72-9864-76578cef2527",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_7",
                    "encounterId": "5766a124-5343-48f2-8826-01a809d6bd40",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "62bb09fc-b178-42a4-9e6d-8579b0ad37a5",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "d590ae7d-42e3-4292-ad4e-03d0cdcde29c",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_9",
                    "encounterId": "5c3dccb8-2212-4904-a653-16cd791e6600",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "3b83e57b-a38b-425c-8a15-3517fbb2c2c3",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_10",
                    "encounterId": "e464621d-6d37-451d-9d2c-e06101543298",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "5da055b6-ef3a-4ee6-8811-2bf5603c8536",
                    "activityIds": [
                      "80ae635a-8483-4962-ac55-a687f4b145b2"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_11@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "0d16143e-1429-4066-8bf3-d72028fdf3bf",
                    "activityIds": [
                      "377ff2de-f527-40a7-9dff-14bba0b547d0"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_12@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "c29c24a6-90ee-428c-ac9b-d10686960077",
                    "activityIds": [
                      "cc93b7e9-62e0-4778-9978-630642c114c4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "036d9116-74c1-4589-bc5e-84dabca28574",
                    "activityIds": [
                      "cc93b7e9-62e0-4778-9978-630642c114c4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "20979074-67d2-43ab-9bb0-21dcc3792da5",
                    "activityIds": [
                      "cc93b7e9-62e0-4778-9978-630642c114c4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "07fd4cd2-82ae-476a-92fe-6ec4c4d4f664",
                    "activityIds": [
                      "cc93b7e9-62e0-4778-9978-630642c114c4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "37fc03f8-36ae-498d-950d-8cd69b4a06e3",
                    "activityIds": [
                      "cc93b7e9-62e0-4778-9978-630642c114c4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_13@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "a9506ed1-4016-4266-bead-aeff0bf4a6d6",
                    "activityIds": [
                      "57f57586-6635-4506-98a2-546d6a30c0b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "1502d20b-9b83-42f2-9645-5e6acdcf08ff",
                    "activityIds": [
                      "57f57586-6635-4506-98a2-546d6a30c0b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "d28007f8-c241-4689-8504-05fe415ce3be",
                    "activityIds": [
                      "57f57586-6635-4506-98a2-546d6a30c0b1"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_14@enc_12",
                    "encounterId": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "85318129-9087-4964-abf5-a16e775096ec",
                    "activityIds": [
                      "8d08efbd-f7ee-492b-915b-2875c4a58b42"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_15@enc_14",
                    "encounterId": "a5ab6b5d-33a3-45d2-8da6-f2fea357b749",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "997d48c0-2cd7-453b-8372-44f426b4fce8",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "02424ca4-5ca6-48f6-8c69-21037316100f",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_3",
                    "encounterId": "4bede743-2506-4a46-b81d-593ff9a4a7e9",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "83539bec-ad3a-4737-8954-3fe9b71d496f",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_4",
                    "encounterId": "81574565-1107-4e9b-b767-543a55c669e5",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "e0b30ffb-6a51-4934-9c0e-12a6cbdc3732",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "cf824c4f-2960-4d8f-9ee5-bac5cc7409ee",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_6",
                    "encounterId": "0a49e14a-da14-48a9-ba48-46ed0a926711",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "961a9f5d-9d68-41d9-9eb2-43c2544a2410",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_7",
                    "encounterId": "5766a124-5343-48f2-8826-01a809d6bd40",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "970215b3-9610-4ac4-9ca2-f56c4e7114d8",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "992f428d-f9cd-4811-a895-fc20e87c2b48",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_9",
                    "encounterId": "5c3dccb8-2212-4904-a653-16cd791e6600",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "883347ff-f795-4836-b9f7-5284c58893da",
                    "activityIds": [
                      "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_16@enc_10",
                    "encounterId": "e464621d-6d37-451d-9d2c-e06101543298",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "633c8cd0-0d8f-444f-8c91-2bce843ee7b7",
                    "activityIds": [
                      "f9d3c0d9-a4d8-49e4-92b0-01765ff66432"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "e21c4e8c-75e4-45b3-813c-0d665482b128",
                    "activityIds": [
                      "f9d3c0d9-a4d8-49e4-92b0-01765ff66432"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "894ba676-b203-4982-baa1-8fd35156e922",
                    "activityIds": [
                      "f9d3c0d9-a4d8-49e4-92b0-01765ff66432"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "03fa9a6e-ba26-4650-aca6-94c50d2b7258",
                    "activityIds": [
                      "f9d3c0d9-a4d8-49e4-92b0-01765ff66432"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "b32d4896-5218-46fc-a3d6-028515507356",
                    "activityIds": [
                      "f9d3c0d9-a4d8-49e4-92b0-01765ff66432"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_17@enc_12",
                    "encounterId": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "dffb0789-2c44-408c-865d-f6a2e6131271",
                    "activityIds": [
                      "865e8b2e-5193-418e-b799-d94bbc5c24fa"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_18@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "78e500e8-5f45-4ca4-b0f5-bd381bba9344",
                    "activityIds": [
                      "c9781037-dd1d-4879-b551-100a92c7746b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "20521ca9-dc5a-4a75-9990-1034430cd026",
                    "activityIds": [
                      "c9781037-dd1d-4879-b551-100a92c7746b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "ba161934-ff97-4d39-837f-262e12d4fb34",
                    "activityIds": [
                      "c9781037-dd1d-4879-b551-100a92c7746b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "867c468a-6a07-4084-871b-a20eb906528b",
                    "activityIds": [
                      "c9781037-dd1d-4879-b551-100a92c7746b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_19@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "3c27fd2f-3864-408f-b05e-4bbdb2e94808",
                    "activityIds": [
                      "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "c81b437f-6a8d-4b30-bf23-ac71f0572ace",
                    "activityIds": [
                      "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "b1ff24fe-eb3c-4e3b-a61a-d95d0ec3b8a0",
                    "activityIds": [
                      "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "719927b1-dd4d-448c-a127-d29643ee7bcf",
                    "activityIds": [
                      "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_20@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "4a0c1ab1-5284-4ada-8bd1-50b3ae766422",
                    "activityIds": [
                      "43393633-2657-4df2-b7de-274471bce080"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "bc2d440f-33ad-4f09-a804-d56b72cfb9d1",
                    "activityIds": [
                      "43393633-2657-4df2-b7de-274471bce080"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "751f001e-b79c-47f6-a86d-f504ccebfc8c",
                    "activityIds": [
                      "43393633-2657-4df2-b7de-274471bce080"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_21@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "935b40ee-ff74-43e2-b98d-6a9105a3da28",
                    "activityIds": [
                      "af7eaa46-11a7-4396-8a4f-c91fdb47c498"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "18fa60c9-0870-4ccc-8f6f-386426557a3f",
                    "activityIds": [
                      "af7eaa46-11a7-4396-8a4f-c91fdb47c498"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "5b16329b-bfac-400a-bfe8-076c09b4db3d",
                    "activityIds": [
                      "af7eaa46-11a7-4396-8a4f-c91fdb47c498"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "137637fa-ecaa-4fcc-87b9-84eeaf5a2202",
                    "activityIds": [
                      "af7eaa46-11a7-4396-8a4f-c91fdb47c498"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_22@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "3c8106a2-24ed-4bdd-9b90-3da2b7afed9a",
                    "activityIds": [
                      "706e29cf-3fa9-4154-866e-6298967d6cc0"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_23@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "b60c6daf-5ade-486c-9e66-6ab2e64395a5",
                    "activityIds": [
                      "512060d9-eea2-40cc-8e8f-7a2daadc779f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "3ee644bc-e2f0-4892-ba54-3d96d3d81cb1",
                    "activityIds": [
                      "512060d9-eea2-40cc-8e8f-7a2daadc779f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_5",
                    "encounterId": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "0f49c8ac-43fd-4b53-93d1-45cf7439afce",
                    "activityIds": [
                      "512060d9-eea2-40cc-8e8f-7a2daadc779f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "49a168dd-3a4f-44d0-8581-754a98793b34",
                    "activityIds": [
                      "512060d9-eea2-40cc-8e8f-7a2daadc779f"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_24@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "923ab9b8-c4c9-4ec5-add8-380ed82a6059",
                    "activityIds": [
                      "e87b0558-152c-4f92-9f9e-fd7d7c60fc5b"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_25@enc_2",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "55d0fe11-2720-4866-b1ca-1e9420759f3a",
                    "activityIds": [
                      "71cc27da-22ef-4013-9416-84ee3b7295a4"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_26@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "be39126f-91e1-4e01-b876-04339b6acd1e",
                    "activityIds": [
                      "c04467fa-c66e-4fe5-96e4-096b5982718a"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_27@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "a1138d6b-b2bb-4d9c-8655-de7a97a3a7b0",
                    "activityIds": [
                      "04432ef2-90f3-450a-b914-fc58628dfc7d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_1",
                    "encounterId": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "2a6f2133-d12e-4b5e-b6af-98e21d42187a",
                    "activityIds": [
                      "04432ef2-90f3-450a-b914-fc58628dfc7d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_8",
                    "encounterId": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                    "timingId": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae"
                  },
                  {
                    "id": "625cadea-beab-4965-bd6d-ec952e18dac6",
                    "activityIds": [
                      "04432ef2-90f3-450a-b914-fc58628dfc7d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_11",
                    "encounterId": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                    "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1"
                  },
                  {
                    "id": "54bdbb07-4698-474d-b1c0-6e5c9ed072a9",
                    "activityIds": [
                      "04432ef2-90f3-450a-b914-fc58628dfc7d"
                    ],
                    "instanceType": "ScheduledActivityInstance",
                    "name": "act_28@enc_13",
                    "encounterId": "3b8059a3-19a6-46ee-9371-03ef3529d828",
                    "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4"
                  },
                  {
                    "id": "9e715e14-8435-481b-b39e-c49dcebf9a26",
                    "name": "Anchor: FirstDose",
                    "description": "Time anchor for scheduling: FirstDose",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "be12b8c1-3306-4f99-b73e-fe7987b65d79",
                    "name": "Anchor: Randomization",
                    "description": "Time anchor for scheduling: Randomization",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "a894b4bb-42f0-49b2-9d93-d9772695e301",
                    "name": "Anchor: Day1",
                    "description": "Time anchor for scheduling: Day1",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "9347347d-8257-44d6-af30-7577412b9f5c",
                    "name": "Anchor: Screening",
                    "description": "Time anchor for scheduling: Screening",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "67cc3a1d-fd27-455c-bc06-f4d2aca08376",
                    "name": "Anchor: InformedConsent",
                    "description": "Time anchor for scheduling: InformedConsent",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "81ca7075-e335-43b1-a7bb-b7d6bf7804f0",
                    "name": "Anchor: Custom",
                    "description": "Time anchor for scheduling: Custom",
                    "encounterId": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                    "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "3f16e0bb-573c-4609-a033-3835429e387d",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "scheduledDay": 1
                  },
                  {
                    "id": "82e34612-2631-4041-b038-9f6b472ec261",
                    "name": "Auto-anchor for Pembrolizumab Cycle Window",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "f2dbeeb4-e590-4a45-abfb-16fc9b43f8e3",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "3f7fac8c-47cd-4da2-bda9-bd32a4c3bc03",
                    "name": "Auto-anchor for Adverse Event Monitoring",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "89c15d95-0a1c-43a6-a059-c8b3b9472efc",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "109f2c67-489a-431d-ad15-e681c7c3da67",
                    "name": "Auto-anchor for Serious Adverse Event Collection",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "9bca9fc7-cdca-481a-987d-65a0c9ea2c90",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "19340055-5cc0-403a-90b5-b81867a86dd0",
                    "name": "Auto-anchor for Contraception Period (Pembrolizumab)",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "b6dfdcf7-0993-49f5-a3b6-6f6e30d67389",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  },
                  {
                    "id": "db1dd4ec-648f-4803-946c-677404f8306e",
                    "name": "Auto-anchor for Contraception Period (Chemotherapy)",
                    "activityIds": [],
                    "instanceType": "ScheduledActivityInstance",
                    "extensionAttributes": [
                      {
                        "id": "255e951b-9c30-4a23-b3fc-20503b5a31d3",
                        "url": "http://example.org/usdm/instanceSource",
                        "instanceType": "ExtensionAttribute",
                        "valueString": "execution_model"
                      }
                    ],
                    "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f"
                  }
                ],
                "timings": [
                  {
                    "id": "3183208b-d876-4041-9ac4-5ba59e3a32d8",
                    "name": "Screening Window",
                    "type": {
                      "id": "8eeb4026-190b-422a-a848-1dd6e6f0344a",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P28D",
                    "valueLabel": "Day 28",
                    "relativeToFrom": {
                      "id": "b9ba5312-de9d-4a4a-9597-e7625687b292",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "9347347d-8257-44d6-af30-7577412b9f5c",
                    "instanceType": "Timing",
                    "windowLower": "-P28D",
                    "windowUpper": "-P1D"
                  },
                  {
                    "id": "b5a14cf3-53a2-4b74-af14-dd4f6960d35d",
                    "name": "Cycle 1 Day 1 Start",
                    "type": {
                      "id": "0cd255fe-d0e0-4bd2-9055-0ae2a2c27bff",
                      "code": "C71151",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Within",
                      "instanceType": "Code"
                    },
                    "value": "P3D",
                    "valueLabel": "Day 3",
                    "relativeToFrom": {
                      "id": "1d35a75a-ac7b-40be-8393-cb22625cc284",
                      "code": "C71154",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Randomization",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "9e715e14-8435-481b-b39e-c49dcebf9a26",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P3D"
                  },
                  {
                    "id": "411f95d8-5037-4d6f-901f-afc57eeba565",
                    "name": "Pembrolizumab Cycle Window",
                    "type": {
                      "id": "49cfe047-7fc9-4171-b257-a51497d4ea5f",
                      "code": "C71148",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Fixed Reference",
                      "instanceType": "Code"
                    },
                    "value": "P21D",
                    "valueLabel": "Day 21",
                    "relativeToFrom": {
                      "id": "6ad0e4ba-fc38-4a56-89ee-4bed7e3221c4",
                      "code": "C71157",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Previous Visit",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "82e34612-2631-4041-b038-9f6b472ec261",
                    "instanceType": "Timing",
                    "windowLower": "-P3D",
                    "windowUpper": "P3D"
                  },
                  {
                    "id": "2c5b5316-b072-46db-b2af-537b080115c5",
                    "name": "Adverse Event Monitoring",
                    "type": {
                      "id": "40d95772-8039-41d9-9a00-6fcfc6620784",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P30D",
                    "valueLabel": "Day 30",
                    "relativeToFrom": {
                      "id": "a0323568-f2ab-49c7-95b9-16675e13abb3",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "3f7fac8c-47cd-4da2-bda9-bd32a4c3bc03",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P30D"
                  },
                  {
                    "id": "93549d18-cdc1-4ee4-a43d-29faff25c575",
                    "name": "Serious Adverse Event Collection",
                    "type": {
                      "id": "f6311143-4f76-402e-b34b-32c3727d3957",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P90D",
                    "valueLabel": "Day 90",
                    "relativeToFrom": {
                      "id": "e66798cc-6f78-4252-bf3f-fc0dac3f8c03",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "109f2c67-489a-431d-ad15-e681c7c3da67",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P90D"
                  },
                  {
                    "id": "78e5be2b-d6a3-4898-b996-94a0050dc5e7",
                    "name": "Contraception Period (Pembrolizumab)",
                    "type": {
                      "id": "385914c9-9f76-428b-a229-9ebbe0dc7ce2",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P120D",
                    "valueLabel": "Day 120",
                    "relativeToFrom": {
                      "id": "45295779-d72b-4c5e-8920-c080cb90f685",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "19340055-5cc0-403a-90b5-b81867a86dd0",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P120D"
                  },
                  {
                    "id": "389c7ae9-58ab-43eb-b982-658b500bac54",
                    "name": "Contraception Period (Chemotherapy)",
                    "type": {
                      "id": "553f1b83-ba87-415c-bd24-28c21a0e90d1",
                      "code": "C71150",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "After",
                      "instanceType": "Code"
                    },
                    "value": "P180D",
                    "valueLabel": "Day 180",
                    "relativeToFrom": {
                      "id": "4a08b797-aa0e-4b70-aa4e-24280bddd083",
                      "code": "C71156",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Last Dose",
                      "instanceType": "Code"
                    },
                    "relativeFromScheduledInstanceId": "db1dd4ec-648f-4803-946c-677404f8306e",
                    "instanceType": "Timing",
                    "windowLower": "P0D",
                    "windowUpper": "P180D"
                  }
                ],
                "exits": [
                  {
                    "id": "08a12805-9bf1-4f10-874a-7bc03c742d9b",
                    "name": "Maximum Treatment Duration",
                    "exitType": "Completion",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Pembrolizumab treatment may continue until 35 treatments (approx. 2 years)."
                  },
                  {
                    "id": "deae49cb-7f48-4a60-a789-8c5ba0b4ac57",
                    "name": "Early Trial Termination",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Termination due to inaccurate/incomplete data or poor protocol adherence."
                  },
                  {
                    "id": "c349f931-8bf7-4d66-98db-ff4fd75ea19c",
                    "name": "Withdrawal of Consent",
                    "exitType": "Early Termination",
                    "instanceType": "ScheduleTimelineExit",
                    "description": "Subject or representative withdraws consent from the trial."
                  }
                ]
              }
            ],
            "encounters": [
              {
                "id": "dd94cac3-4644-4c6e-8fc3-6202b2bdf527",
                "name": "Cycle 1 Day 1",
                "instanceType": "Encounter",
                "type": {
                  "id": "fcd38670-711f-4f19-8263-f53a425da409",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "f83d5d88-94f6-4960-82f9-cf60b89b9f88",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "4bdac6cf-200a-42a3-b141-cbac3e0aa9dc",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "36113026-bfda-4a82-922b-714874b53cd5",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "d7ab9bca-f662-4360-9aa0-cdc3f8d80a49",
                "name": "Cycle 2 Day 1",
                "instanceType": "Encounter",
                "type": {
                  "id": "b58f07b1-60e6-45e2-8032-8d10be72c284",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "b5784d92-102a-4741-8019-f8b066ad3049",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8d9fc23e-7db6-4138-8aae-cbe0070097a6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "efb8c38a-0e35-41d5-bfca-dbdc5595f32f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "71faeba8-cccf-4beb-8be2-2569c0e155d8",
                "name": "Cycle 3 and Beyond Day 1",
                "instanceType": "Encounter",
                "type": {
                  "id": "3bbf9635-dcf1-4fd8-b79a-88cc1fc495fc",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "5013b330-0546-4f35-a45a-aee7bca27fbf",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1363a07d-fd81-407b-a76a-d737ee88422f",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "e3e7ffff-607b-4733-ae1f-2fd09d55abe0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 1
                  }
                ]
              },
              {
                "id": "4bede743-2506-4a46-b81d-593ff9a4a7e9",
                "name": "Cycle 1 Day 8",
                "instanceType": "Encounter",
                "type": {
                  "id": "d744083a-ee0f-474b-a86e-873edf30c51d",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "151aee9d-3a57-44e5-9f18-fa4933a44c37",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "1842d7ca-e46b-4f88-b5a6-e3a38a76bf9d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "bb56ea2a-f9ee-4dbd-8978-26b41b5ef736",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 8
                  }
                ]
              },
              {
                "id": "0a49e14a-da14-48a9-ba48-46ed0a926711",
                "name": "Cycle 2 Day 8",
                "instanceType": "Encounter",
                "type": {
                  "id": "76f21b85-71f5-4273-bca0-67e8b85048a9",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "c060a7bb-91b5-4221-9fa5-ce41715b023c",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8aa1cd51-c65b-4f81-9eb6-51ca98a76344",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "dc57d48f-c73c-4a60-a8b3-556c9be53143",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 8
                  }
                ]
              },
              {
                "id": "5c3dccb8-2212-4904-a653-16cd791e6600",
                "name": "Cycle 3 and Beyond Day 8",
                "instanceType": "Encounter",
                "type": {
                  "id": "bfa7789c-6b2e-40a9-85c1-7cdd0460e3c6",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "ad5f050b-4cee-46c7-b8ec-e9d65e2bf3e3",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ac088b47-eb99-425f-96ba-1eb6ba638784",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "8a9fb952-1d18-404c-9420-3a4c666803a6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 8
                  }
                ]
              },
              {
                "id": "81574565-1107-4e9b-b767-543a55c669e5",
                "name": "Cycle 1 Day 15",
                "instanceType": "Encounter",
                "type": {
                  "id": "5ebfa97f-9a02-40fe-bdcc-d73e4bd44976",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "b164af7e-cfab-4cf5-a629-9d4265ca2d6b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "331204aa-9ec3-4955-8059-25a74b81f348",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "97e14f1f-87f4-47c6-bdcf-166371d7df02",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "5766a124-5343-48f2-8826-01a809d6bd40",
                "name": "Cycle 2 Day 15",
                "instanceType": "Encounter",
                "type": {
                  "id": "a57ecf4f-de7d-4c21-a7fe-92f6abfc676a",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "be8de0f4-7388-46d1-8f94-b2bbd20cfebe",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ca2e959b-3845-4661-9f6c-23f9f0bc2bea",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "eb4f6036-a628-4be9-b53e-6e91739e0f5a",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "e464621d-6d37-451d-9d2c-e06101543298",
                "name": "Cycle 3 and Beyond Day 15",
                "instanceType": "Encounter",
                "type": {
                  "id": "4e5411f9-311f-431b-bf3c-ee806e502447",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "extensionAttributes": [
                  {
                    "id": "3aad7365-2b0b-4a72-ada0-981be8c2f48e",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6ebe365e-a692-46f2-a9e6-c82e29c9d892",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  },
                  {
                    "id": "a2fc9616-85ef-4951-be59-e8204ff9bb2b",
                    "url": "https://protocol2usdm.io/extensions/x-encounterStudyDay",
                    "instanceType": "ExtensionAttribute",
                    "valueInteger": 15
                  }
                ]
              },
              {
                "id": "9068163d-c95d-42d3-954f-cf8677b3bdca",
                "name": "Discontinuation",
                "instanceType": "Encounter",
                "type": {
                  "id": "13004f84-a480-4bf2-9b6b-c40a0cfba844",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1",
                "extensionAttributes": [
                  {
                    "id": "d5468763-1761-4b82-ad18-a490556da0e6",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "6c597896-edf6-401e-a84e-57af235303c0",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "3b8059a3-19a6-46ee-9371-03ef3529d828",
                "name": "Follow Up Visits",
                "instanceType": "Encounter",
                "type": {
                  "id": "913d59ea-2e9e-4c82-bd34-13a7a55b6a28",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Study Visit",
                  "instanceType": "Code"
                },
                "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "extensionAttributes": [
                  {
                    "id": "9b064878-0040-4485-b0af-c31336268b98",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c9acfdb3-7f88-4a51-b870-6dd815c436f7",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "82a700ce-4b56-4bf7-b1bf-4d1eba0db8d9",
                "name": "Safety Follow-up",
                "instanceType": "Encounter",
                "type": {
                  "id": "bb213d82-0317-4137-9ffb-6e7685a132cb",
                  "code": "C98777",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Visit",
                  "instanceType": "Code"
                },
                "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "extensionAttributes": [
                  {
                    "id": "b69f2175-da43-48e2-9d22-dd17d84c031d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b74a1b33-b4e5-49bd-ab78-e6e2b19e85c4",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "d6cf9d3b-e537-4519-9a62-6e725eaf2335",
                "name": "Screening (Visit 1)",
                "instanceType": "Encounter",
                "type": {
                  "id": "d1c460a4-d2e3-425a-bca9-1f53b4b4708d",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Visit",
                  "instanceType": "Code"
                },
                "epochId": "50139ff7-da46-485e-90e3-fb541ae8502f",
                "extensionAttributes": [
                  {
                    "id": "125815b0-1869-4dbb-8c38-3804573da58d",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f4372798-46ab-4ec6-a19e-d03cb55802a9",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              },
              {
                "id": "a5ab6b5d-33a3-45d2-8da6-f2fea357b749",
                "name": "Survival Follow-Up",
                "instanceType": "Encounter",
                "type": {
                  "id": "769c0412-4d6f-433e-90b1-7f5300cb00ec",
                  "code": "C98777",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Follow-up Visit",
                  "instanceType": "Code"
                },
                "epochId": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "extensionAttributes": [
                  {
                    "id": "796c5b5a-1e30-4757-820a-70c2a4292799",
                    "url": "https://protocol2usdm.io/extensions/x-encounterSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "140c4c1a-06c3-4627-83c3-6c1cf00654a3",
                    "url": "https://protocol2usdm.io/extensions/x-encounterType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "visit"
                  }
                ]
              }
            ],
            "activities": [
              {
                "id": "9eed301f-8791-408d-82b8-126cf08ed236",
                "name": "12-Lead Electrocardiogram",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "6fb1a929-7fe6-4ae5-88b4-be23117e8266",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "31de8f0f-0af7-4ead-b9a8-06cc98bb4a8d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "7aca9cfa-f8ff-4deb-bd75-8bd65ef4e779",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "377ff2de-f527-40a7-9dff-14bba0b547d0",
                "name": "12-Lead Electrocardiogram (Local)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2acb6045-fa18-4846-9e86-e49b8d31355f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f3cf02b4-0f12-42a2-ac00-a68cfd1e26da",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7267188e-3c91-46d8-98fe-253502338122",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c04467fa-c66e-4fe5-96e4-096b5982718a",
                "name": "Archival Tumor Tissue",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "529e69aa-398b-4734-a169-5709f84b769e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "b356aeb7-597a-447c-9e0a-bf4a37690f48",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "20d24d93-d3c9-4774-8810-65487691b086",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a6bf5ced-3c16-4176-a622-37f842edbf9e",
                "name": "Blood Collection",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "05076ca0-b194-4245-8b9c-1a6771b439ca",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "d51bcd69-ec70-4c54-8e06-eeae39e5c1ec",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "ec766cb2-368d-44bc-b632-71ff2b4b041c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "706e29cf-3fa9-4154-866e-6298967d6cc0",
                "name": "Blood for Genetics",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e0722801-4c76-40f7-abbf-1eb753de9e0e",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "26ac6562-20d3-48b6-90b6-360becdaf7cf",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "483d6fcb-febc-44b5-91b4-572a5e1eb736",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "78d6bd70-7b6d-411f-908e-133ce360be2a",
                "name": "Bronchoscopy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "78d6bd70-7b6d-411f-908e-133ce360be2a",
                    "name": "Bronchoscopy",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "b0b8d039-6510-4732-8bb8-e7869423e661",
                      "code": "C25391",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Diagnostic Procedure",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Bronchoscopy",
                    "description": "Procedure to evaluate suspected pneumonitis"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "36630437-2d2c-467b-937e-f4b47cf32bbe",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "d962e605-c737-4c63-b1b8-161001368756",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "93465549-e085-44a6-b275-d3618e2ca90c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "c9781037-dd1d-4879-b551-100a92c7746b",
                "name": "CBC with Differential",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a6cd7bac-1718-4fa7-98c7-4791bd299f8a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "c0ae49db-c35f-40fc-a888-c48ad62c2ca2",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "fc78bb26-d454-4ffe-b59c-feb0cb369edd",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9",
                "name": "Chemistry Panel",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "c5170e54-977c-4610-a22c-d75a52a71bc8",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f66b0fa2-3fbe-45f8-94db-8ac8a4c23276",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "5f4f7a92-186c-4cc9-a03e-d2cc7304b737",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "4cdd7aef-e8c2-4c17-9eb0-2435e9bdcebe",
                "name": "Demographics and Medical History",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "8bb8893e-45ce-45bb-afa9-d8f6c9a16cda",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "52b46e0b-574d-4202-a67a-4415397b5712",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "51377d1d-2db4-409d-acff-51f95e4d3dd7",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "a8eb24a7-3e8c-48e0-8114-8bb13823064c",
                "name": "Directed Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2e8d55bb-76fc-46cf-94b4-35c3304b161b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "dc152317-6cf2-4bc8-990e-b1fa58a23e41",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "dfc9afab-7b0f-4269-9f28-36d845ee319b",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "cc93b7e9-62e0-4778-9978-630642c114c4",
                "name": "ECOG Performance Status",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "d0def327-18a1-4f12-8ea2-5c6880eb0022",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "e5d52964-43e5-49d6-95b6-d26f6efc343b",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "6898515f-b05b-43a7-94ce-db6bfd243167",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "53302258-0d5c-4512-aec5-5381e0c7ae84",
                "name": "Endoscopy",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "53302258-0d5c-4512-aec5-5381e0c7ae84",
                    "name": "Endoscopy",
                    "procedureType": "Diagnostic Procedure",
                    "code": {
                      "id": "fc5c52e3-253e-47e0-8932-74bcd33535d0",
                      "code": "C25391",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Diagnostic Procedure",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "Endoscopy",
                    "description": "Procedure to evaluate suspected colitis or other irAEs"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "a85fc6db-c8ba-4c03-8902-f18baf5ab57c",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "1a8ca615-03e4-4a3c-8f09-5549c08252a7",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "4dbca75d-debd-4e96-8a4b-64539f29fb92",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "bc36a2e3-d5df-465c-af90-aa67e4b2402c",
                "name": "Full Physical Examination",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "17a00ca1-6db3-4ac2-be65-b1c78b1f650a",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "3a498c0b-2aeb-4514-bbac-1214d4a5fc55",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "670cd92a-c2a9-4a80-80c3-2de1e8d8acb5",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "80ae635a-8483-4962-ac55-a687f4b145b2",
                "name": "Height, Weight, and Vital Signs (T,P,RR,BP)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "5789a71b-0b5e-4a24-9fbf-aa64f9ce6fd3",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "64cdd47a-8fc7-47f8-8905-8ed8b54993d0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "d5d382cf-a412-450d-b0f7-53aea5b93982",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "47096d32-fd68-4d8a-8703-bd3c0bbeb448",
                "name": "Inclusion/Exclusion Criteria",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "2895ac33-bcba-422f-a19c-f720e3ec5cbe",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "110ead20-452d-4282-a088-2f492469dee0",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "116f84b7-f9f7-45ce-9f0f-1c6f60a5fb48",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "1ad03d4c-46a5-482d-adeb-f69e64931cdb",
                "name": "Informed Consent",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "965fc3c2-e327-4adf-b7e8-6e6f85a73b22",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ca358263-0ec8-425a-957c-175b1776c387",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "488b0f98-c021-4488-9346-309782f96d42",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "07ae87b8-4509-4f42-a2bf-de69abc77d65",
                "name": "Informed Consent for Future Biomedical Research (optional)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "54fff0e7-f00c-4707-a870-cd57fa3ac042",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ff3f0731-dd2f-442a-98ab-9bf63a544c92",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "documentation"
                  },
                  {
                    "id": "982f9f2f-7ee3-4895-8bd5-ea9fcfc6b701",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "94e3f1d0-f298-4081-a6e7-4ff40fb67b3e",
                "name": "Intravenous Infusion",
                "instanceType": "Activity",
                "definedProcedures": [
                  {
                    "id": "94e3f1d0-f298-4081-a6e7-4ff40fb67b3e",
                    "name": "Intravenous Infusion",
                    "procedureType": "Therapeutic Procedure",
                    "code": {
                      "id": "8adc6ff3-7c00-4e2e-9555-f656d1de9b70",
                      "code": "C49236",
                      "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                      "codeSystemVersion": "25.01d",
                      "decode": "Therapeutic Procedure",
                      "instanceType": "Code"
                    },
                    "instanceType": "Procedure",
                    "label": "IV Infusion",
                    "description": "Administration of study treatment via intravenous route"
                  }
                ],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ece1a91a-c128-4dde-8aa4-bf0e982e0353",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "8e5688bd-7216-44fc-a14d-e4b7dc78d59e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "0ab6c83d-0362-46b0-acdd-2f0bb5c75430",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "71cc27da-22ef-4013-9416-84ee3b7295a4",
                "name": "Newly-Obtained Tumor Tissue",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "e94ee2c9-db79-4da5-9c9c-8da5eb2f02ff",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "bae5ba84-3f03-44b2-a51f-32c31582764e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "7932d2a6-5aab-4b36-9a8f-a639862e53c0",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "57f57586-6635-4506-98a2-546d6a30c0b1",
                "name": "PROs (HRQoL Measures)",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "253a2453-fdd8-4f04-8d14-b08919eb68ba",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8ea8f4d2-5bad-498b-8a2a-75ca229e89dc",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "f44d04b7-9cbf-4cd8-bbcb-fa7349f2be89",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "865e8b2e-5193-418e-b799-d94bbc5c24fa",
                "name": "PT/INR and aPTT",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "ca61da16-8dd5-4f45-8441-3378ceb63532",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "961951ec-ec3e-461f-a44b-c26258adb854",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "6352ea54-4b39-45c8-8dff-fa1fd347858f",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "aab11cc4-38f5-4a63-94ef-5bfc2c102958",
                "name": "Paclitaxel Administration",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "890e3056-273b-42a4-9380-327ab59d9ea9",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "8bdd1b30-a8bd-4b84-87cb-66ef5fef828e",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "administration"
                  },
                  {
                    "id": "c3dc8cbc-5e61-4803-a08a-c8c8e0dc8dd9",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "b77dca02-de31-45f2-8122-98163f05fbe1",
                "name": "Physical Exam",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "eca469f7-268b-497a-877c-eaf771c33153",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "a656bdff-6140-4105-bac0-2fc6a7686f3d",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "6415fcf0-0173-4424-b125-c810169fb4fa",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "442298d8-8831-4a89-ae30-6befcf07fb98",
                "name": "Post-study Anticancer Therapy Status",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "456a3b7b-d7c0-47e6-abb6-f77ae08617d1",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "ad4429a2-bf0e-4bb3-bed9-9856793d3765",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "93e7aeff-4924-43fa-83ba-801f29ea8629",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "f9d3c0d9-a4d8-49e4-92b0-01765ff66432",
                "name": "Pregnancy Test",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "dfe09cbe-1f9f-4d07-b05d-ec0e334dbdeb",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures,soa"
                  },
                  {
                    "id": "44d0807a-d694-46c3-aea7-fb95111f6a4f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "22cc0977-a965-4ab4-adab-41cbdd4c2882",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "8bff46ca-00a4-4f28-afea-b9239dbe5da6",
                "name": "Prior and Concomitant Medication Review",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "b651bce0-43c9-4424-87f9-746b482b08db",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "96e1d5be-032e-457b-af1f-4777bbed670f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "cf1eac30-68d7-4493-aaa9-10b00b293475",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "d0fe77a2-87d4-4e8b-a190-70b15f1599a8",
                "name": "Review Adverse Events",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7f746436-a9b4-4e80-84ec-2d0d9ac2b0af",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "9b55679f-c047-4d84-a7ca-07f1d27517bb",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "0bbfc00d-86e6-4683-8920-a2304fc3c320",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "39578a9d-9d32-4cbd-8ae2-727e40d59770",
                "name": "Subject Identification Card",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "7747a732-424e-49e1-8c06-05488b5c167b",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f308dfd4-15a1-47da-8243-fa6882e6a5a1",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "9788dda3-f1ac-4393-803a-510c119b5bf3",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "8d08efbd-f7ee-492b-915b-2875c4a58b42",
                "name": "Survival Status",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "bdadd720-26b6-4bd5-920a-e67a8c331483",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "758cc202-66df-4233-bbb4-dbb4ae4e671f",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "5fa2a7d9-ea0a-4165-be85-83310698bc9d",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "af7eaa46-11a7-4396-8a4f-c91fdb47c498",
                "name": "T3, FT4, and TSH",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "f4d5b722-e307-47f5-a791-08db445cffc4",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "751930f8-927a-4959-8e5e-22e4e1256af7",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "bfc1d33e-defd-4f5c-b4dc-c03af7c4d656",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "04432ef2-90f3-450a-b914-fc58628dfc7d",
                "name": "Tumor Imaging",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "0838dc22-d284-4cfd-b8ae-063a1a4a3db3",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures,soa"
                  },
                  {
                    "id": "a3b0245e-a2bc-4edc-9fc6-44db505fdb87",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "other"
                  },
                  {
                    "id": "db674b25-d889-4c50-8275-677fd5fd468e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "06dfa3d1-a4db-4b15-a531-a6b28e349c24",
                "name": "Tumor Tissue Collection",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "18526ec9-be4a-4231-85c6-0b95da23ffe0",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "ab427f57-f1fd-4adc-afb1-c0c149d99600",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "b2732e1b-b5db-4637-bf33-0d561d3a0a2e",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "43393633-2657-4df2-b7de-274471bce080",
                "name": "Urinalysis",
                "instanceType": "Activity",
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "fe643356-6fb9-498c-b3e3-000ed6d6cd0f",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "f33cf549-83ed-460b-b2f7-15b440112028",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "lab"
                  },
                  {
                    "id": "7c61bea4-fdc6-4952-85d7-def395f79eac",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "50864ab5-f042-4f2f-8aa1-94dd7e51df86",
                "name": "Vital Signs",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "820d60f6-c70b-4625-81ff-98d3fba89e38",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedures"
                  },
                  {
                    "id": "0e919fc6-38d3-4b4d-953e-c97858a261bb",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "2baad4bb-3af9-472a-a3ca-d57d62a9fe80",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "procedure_enrichment",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "e87b0558-152c-4f92-9f9e-fd7d7c60fc5b",
                "name": "Whole Blood for Biomarkers Studies (plasma and serum)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "569ceb68-c58e-41ea-869d-031863b599bd",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "5c08711b-cf67-4422-af78-74daf8414052",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "ffafb9fd-39d9-4c5e-b0e5-93b20dab327c",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              },
              {
                "id": "512060d9-eea2-40cc-8e8f-7a2daadc779f",
                "name": "Whole Blood for Correlative Studies (DNA and RNA)",
                "instanceType": "Activity",
                "definedProcedures": [],
                "biomedicalConcepts": [],
                "extensionAttributes": [
                  {
                    "id": "54cf7210-92e7-4174-b0d5-dc9cf53fe028",
                    "url": "https://protocol2usdm.io/extensions/x-activitySources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "235af801-c83a-4694-9f9b-419a59827725",
                    "url": "https://protocol2usdm.io/extensions/x-activityType",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "procedure"
                  },
                  {
                    "id": "11e6e482-8388-4b6c-9653-64a3268fe1af",
                    "url": "http://example.org/usdm/activitySource",
                    "valueString": "soa",
                    "instanceType": "ExtensionAttribute"
                  }
                ]
              }
            ],
            "epochs": [
              {
                "id": "50139ff7-da46-485e-90e3-fb541ae8502f",
                "name": "Screening Phase",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "d7c2076e-03af-4d99-ac26-bc08be390d37",
                  "code": "C98779",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Screening Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "8fd1c83f-7031-4ea4-a21b-b6586bfc8d7e",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "fc087da1-8993-48d0-97fd-4f9d045db6cd",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "518a0e71-0d97-4aca-9ed6-e57101f32e1d",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "1"
                  }
                ]
              },
              {
                "id": "917ef50e-cbc0-4f32-8116-8ffc3041deae",
                "name": "Treatment Cycles",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "768ddef5-23a9-4a91-94d3-2bfd060b5569",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "1959ac6e-dbc8-4ca3-b956-f558e8d9501c",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "a67a9d6d-114d-411a-9c14-1335747528f6",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "4a2de9ca-4e6d-4c0f-8ace-9b3817d22d6b",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "2"
                  }
                ]
              },
              {
                "id": "070c5651-65bd-49b0-94d8-46fc21ce6df4",
                "name": "Post-treatment",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "500ca015-66fe-4537-a7dc-72842fb8ebd1",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "0d47e813-27fa-45b7-8123-33f07c0b941b",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "traversal,soa"
                  },
                  {
                    "id": "9662087b-089e-4e2c-be5f-fbb5ac004018",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "main"
                  },
                  {
                    "id": "898795b6-1be3-48aa-9503-55fac209e7c8",
                    "url": "https://protocol2usdm.io/extensions/x-epochSequenceOrder",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "3"
                  }
                ]
              },
              {
                "id": "b28d2e86-ee7d-4a12-80ea-28e3d0c500e1",
                "name": "End of Treatment",
                "instanceType": "StudyEpoch",
                "type": {
                  "id": "75001a61-020d-4bad-8f8f-9e9509822339",
                  "code": "C98780",
                  "codeSystem": "http://www.cdisc.org",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Treatment Epoch",
                  "instanceType": "Code"
                },
                "extensionAttributes": [
                  {
                    "id": "272449b8-38f1-444c-b739-46376d771dd8",
                    "url": "https://protocol2usdm.io/extensions/x-studyepochSources",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "soa"
                  },
                  {
                    "id": "df90c07b-3ac3-4a1e-95ee-e3cf91296795",
                    "url": "https://protocol2usdm.io/extensions/x-epochCategory",
                    "instanceType": "ExtensionAttribute",
                    "valueString": "sub"
                  }
                ]
              }
            ],
            "activityGroups": [
              {
                "id": "30910f52-151a-4406-a650-47fb1581994d",
                "name": "Administrative Procedures",
                "description": null,
                "childIds": [
                  "1ad03d4c-46a5-482d-adeb-f69e64931cdb",
                  "07ae87b8-4509-4f42-a2bf-de69abc77d65",
                  "47096d32-fd68-4d8a-8703-bd3c0bbeb448",
                  "39578a9d-9d32-4cbd-8ae2-727e40d59770",
                  "4cdd7aef-e8c2-4c17-9eb0-2435e9bdcebe",
                  "8bff46ca-00a4-4f28-afea-b9239dbe5da6",
                  "442298d8-8831-4a89-ae30-6befcf07fb98"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Informed Consent",
                  "Informed Consent for Future Biomedical Research (optional)",
                  "Inclusion/Exclusion Criteria",
                  "Subject Identification Card",
                  "Demographics and Medical History",
                  "Prior and Concomitant Medication Review",
                  "Post-study Anticancer Therapy Status"
                ]
              },
              {
                "id": "896dca02-a1b6-4bbc-b140-e4dd5d2dbafa",
                "name": "Clinical Procedures/Assessments",
                "description": null,
                "childIds": [
                  "d0fe77a2-87d4-4e8b-a190-70b15f1599a8",
                  "bc36a2e3-d5df-465c-af90-aa67e4b2402c",
                  "a8eb24a7-3e8c-48e0-8114-8bb13823064c",
                  "80ae635a-8483-4962-ac55-a687f4b145b2",
                  "377ff2de-f527-40a7-9dff-14bba0b547d0",
                  "cc93b7e9-62e0-4778-9978-630642c114c4",
                  "57f57586-6635-4506-98a2-546d6a30c0b1",
                  "8d08efbd-f7ee-492b-915b-2875c4a58b42"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Review Adverse Events",
                  "Full Physical Examination",
                  "Directed Physical Examination",
                  "Height, Weight, and Vital Signs (T,P,RR,BP)",
                  "12-Lead Electrocardiogram (Local)",
                  "ECOG Performance Status",
                  "PROs (HRQoL Measures)",
                  "Survival Status"
                ]
              },
              {
                "id": "138de4b1-91ac-4e23-ae69-1f18013ebe17",
                "name": "Trial Treatment Administration",
                "description": null,
                "childIds": [
                  "aab11cc4-38f5-4a63-94ef-5bfc2c102958"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Paclitaxel Administration"
                ]
              },
              {
                "id": "f25386d8-39e5-4b65-9ae6-a85faf5387cf",
                "name": "Laboratory Procedures/Assessments: Analysis performed by LOCAL laboratory",
                "description": null,
                "childIds": [
                  "f9d3c0d9-a4d8-49e4-92b0-01765ff66432",
                  "865e8b2e-5193-418e-b799-d94bbc5c24fa",
                  "c9781037-dd1d-4879-b551-100a92c7746b",
                  "4b2e7f3a-fc7a-4bcd-bc43-4676966450f9",
                  "43393633-2657-4df2-b7de-274471bce080",
                  "af7eaa46-11a7-4396-8a4f-c91fdb47c498"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Pregnancy Test",
                  "PT/INR and aPTT",
                  "CBC with Differential",
                  "Chemistry Panel",
                  "Urinalysis",
                  "T3, FT4, and TSH"
                ]
              },
              {
                "id": "2058d9a8-059b-4538-897a-a4fa84b0875d",
                "name": "Laboratory Procedures/Assessments: Analysis performed by CENTRAL laboratory",
                "description": null,
                "childIds": [
                  "706e29cf-3fa9-4154-866e-6298967d6cc0",
                  "512060d9-eea2-40cc-8e8f-7a2daadc779f",
                  "e87b0558-152c-4f92-9f9e-fd7d7c60fc5b"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Blood for Genetics",
                  "Whole Blood for Correlative Studies (DNA and RNA)",
                  "Whole Blood for Biomarkers Studies (plasma and serum)"
                ]
              },
              {
                "id": "7bdd2ec9-6ed9-41bd-b864-a08cf30c5bd2",
                "name": "Tumor Tissue Collection",
                "description": null,
                "childIds": [
                  "71cc27da-22ef-4013-9416-84ee3b7295a4",
                  "c04467fa-c66e-4fe5-96e4-096b5982718a"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Newly-Obtained Tumor Tissue",
                  "Archival Tumor Tissue"
                ]
              },
              {
                "id": "59669129-3bbc-47e7-8ed7-3d8867eb6b7c",
                "name": "Efficacy Measurements",
                "description": null,
                "childIds": [
                  "04432ef2-90f3-450a-b914-fc58628dfc7d"
                ],
                "instanceType": "Activity",
                "activityNames": [
                  "Tumor Imaging"
                ]
              }
            ],
            "notes": [
              {
                "id": "05f20129-0fef-4864-980e-eeb93baf62b7",
                "text": "a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0ab95036-e6d3-43d8-8db5-8ece8b296750",
                "text": "b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of pembrolizumab may be administered up to 3 days after randomization.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "cf72e7d9-8390-4bee-933d-aa109d273949",
                "text": "c. SAEs will be followed through 90 days following cessation of treatment, or 30 days if the subject initiates new anticancer therapy.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "7e2a1cb5-61ed-4df9-b798-0d92b8e1f4e2",
                "text": "d. Height will be measured at Visit 1 only.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a433120d-8ff1-4828-a6ad-b71a4cdc67bc",
                "text": "e. ECOG Performance Status and Laboratory tests for screening are to be performed within 3 days prior to the first dose.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "0ad73542-3010-4047-b38a-c2c0f8d70e81",
                "text": "f. PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle 7, PROs are to be performed every 3 cycles.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "1404838a-8d69-4565-86b4-bb3f0292fe8a",
                "text": "g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "f7114eff-b9d5-4334-9524-00406788bb3b",
                "text": "h. Urinalysis and thyroid function tests are performed Day 1 of every other cycle. CBC and Chemistry to be performed every cycle.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "5f3b9e0f-1832-4417-b491-2087788d8b60",
                "text": "i. Detailed instructions for the collection and management of specimens are provided in the Central Lab Manual.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "c2728d8e-34d8-48f8-9da6-49a10ada9f64",
                "text": "j. Whole blood samples for correlative studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "3a2b1e18-307a-4d02-a6da-1c5eb240c476",
                "text": "k. Newly-obtained tissue is preferred (no intervening treatment involving the site of tissue biopsy once tissue biopsy is obtained).",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "270b4881-b1be-4830-8e13-dc64202f64a6",
                "text": "l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "522189c5-693c-4fba-9545-560ea95c2cf4",
                "text": "m. Screening tumor imaging will be performed within 14 days prior to randomization.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "b218c226-04fc-478d-83ee-add3ff354a1a",
                "text": "n. The first on-study imaging time point will be performed at 9 weeks (63 days ± 7 days) calculated from the date of allocation.",
                "instanceType": "CommentAnnotation"
              },
              {
                "id": "a9320eca-3f7e-4ead-aa51-eb1e5917f56e",
                "text": "d. Height will be measured at Visit 1 only.",
                "instanceType": "Note"
              }
            ],
            "model": {
              "id": "ea8225fa-c1bb-4084-a492-4db5423fde4c",
              "code": "C82639",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Parallel Study",
              "instanceType": "Code"
            },
            "indications": [
              {
                "id": "1e9a1ef7-7fdb-49c3-818c-1aed02d64484",
                "name": "Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus",
                "isRareDisease": false,
                "instanceType": "Indication",
                "description": "Subjects with esophageal cancer that have progressed after first-line standard therapy"
              }
            ],
            "procedures": [
              {
                "id": "94e3f1d0-f298-4081-a6e7-4ff40fb67b3e",
                "name": "Intravenous Infusion",
                "procedureType": "Therapeutic Procedure",
                "code": {
                  "id": "8adc6ff3-7c00-4e2e-9555-f656d1de9b70",
                  "code": "C49236",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Therapeutic Procedure",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "IV Infusion",
                "description": "Administration of study treatment via intravenous route"
              },
              {
                "id": "53302258-0d5c-4512-aec5-5381e0c7ae84",
                "name": "Endoscopy",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "fc5c52e3-253e-47e0-8932-74bcd33535d0",
                  "code": "C25391",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Diagnostic Procedure",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Endoscopy",
                "description": "Procedure to evaluate suspected colitis or other irAEs"
              },
              {
                "id": "78d6bd70-7b6d-411f-908e-133ce360be2a",
                "name": "Bronchoscopy",
                "procedureType": "Diagnostic Procedure",
                "code": {
                  "id": "b0b8d039-6510-4732-8bb8-e7869423e661",
                  "code": "C25391",
                  "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                  "codeSystemVersion": "25.01d",
                  "decode": "Diagnostic Procedure",
                  "instanceType": "Code"
                },
                "instanceType": "Procedure",
                "label": "Bronchoscopy",
                "description": "Procedure to evaluate suspected pneumonitis"
              }
            ],
            "analysisPopulations": [
              {
                "id": "909cbd6d-f210-4010-9904-382d57fb5972",
                "name": "Intention-to-Treat population",
                "text": "The Intention-to-Treat (ITT) population will serve as the population for primary efficacy analysis. All randomized subjects will be included in this population. Subjects will be included in the treatment group to which they are randomized.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "ITT",
                "populationDescription": "The Intention-to-Treat (ITT) population will serve as the population for primary efficacy analysis. All randomized subjects will be included in this population. Subjects will be included in the treatment group to which they are randomized.",
                "criteria": "All randomized subjects"
              },
              {
                "id": "fcc3fd40-a7c9-4331-bbfd-9befb87ed5ab",
                "name": "All Subjects as Treated population",
                "text": "The ASaT population consists of all randomized subjects who received at least one dose of study treatment. Subjects will be included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "ASaT",
                "populationDescription": "The ASaT population consists of all randomized subjects who received at least one dose of study treatment. Subjects will be included in the treatment group corresponding to the study treatment they actually received for the analysis of safety data using the ASaT population.",
                "criteria": "Randomized AND received >=1 dose of study treatment"
              },
              {
                "id": "f7ba72ff-905b-4071-a5d0-c095e23f4fdc",
                "name": "China Cohort (Efficacy)",
                "text": "The Chinese subjects randomized after the enrollment of the Global Cohort is closed will not be included in the above primary efficacy analysis population which is based on the Global Cohort. The China Cohort will also be analyzed separately per local regulatory requirement.",
                "populationType": "Efficacy",
                "instanceType": "AnalysisPopulation",
                "label": "China Cohort",
                "populationDescription": "The Chinese subjects randomized after the enrollment of the Global Cohort is closed will not be included in the above primary efficacy analysis population which is based on the Global Cohort. The China Cohort will also be analyzed separately per local regulatory requirement.",
                "criteria": "Chinese subjects randomized after Global Cohort enrollment closed"
              },
              {
                "id": "12be1676-ac9d-4f39-9530-c3e8f4d559a6",
                "name": "China Cohort (Safety)",
                "text": "The Chinese subjects randomized and treated in the China extension enrollment period will not be included in the above primary safety analysis population. The China Cohort will also be analyzed separately per local regulatory requirement.",
                "populationType": "Safety",
                "instanceType": "AnalysisPopulation",
                "label": "China Cohort",
                "populationDescription": "The Chinese subjects randomized and treated in the China extension enrollment period will not be included in the above primary safety analysis population. The China Cohort will also be analyzed separately per local regulatory requirement.",
                "criteria": "Chinese subjects randomized and treated in the China extension enrollment period"
              }
            ],
            "characteristics": [
              {
                "id": "016e1635-23c5-45a1-a885-dbffee5b7789",
                "code": "SQUAMOUS_CELL_CARCIN",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Squamous cell carcinoma of the esophagus",
                "instanceType": "Code"
              },
              {
                "id": "4f18256c-6b42-4ba2-9187-73a5ff610fff",
                "code": "PD-L1_CPS≥10",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "PD-L1 CPS≥10",
                "instanceType": "Code"
              },
              {
                "id": "9a7a652c-0f7c-4aeb-a023-a9a113c91745",
                "code": "REGION",
                "codeSystem": "http://www.cdisc.org/baseline-characteristics",
                "codeSystemVersion": "2024-03-29",
                "decode": "Region",
                "instanceType": "Code"
              }
            ],
            "extensionAttributes": [
              {
                "id": "f71c9ed9-1b9f-4f85-9dca-5136a726c471",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-entityMaps",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"epochAliases\": {\"SCREENING PHASE\": \"epoch_1\", \"SCREENING_PHASE\": \"epoch_1\", \"SCREENING\": \"epoch_1\", \"TREATMENT CYCLES\": \"epoch_2\", \"TREATMENT_CYCLES\": \"epoch_2\", \"TREATMENT\": \"epoch_4\", \"END OF TREATMENT\": \"epoch_3\", \"END_OF_TREATMENT\": \"epoch_3\", \"POST-TREATMENT\": \"epoch_4\", \"POST_TREATMENT_FOLLOW_UP\": \"epoch_4\", \"SAFETY_FOLLOW_UP\": \"epoch_4\", \"INITIAL_TREATMENT_PHASE\": \"epoch_2\", \"SURVIVAL_FOLLOW_UP\": \"epoch_4\"}, \"visitAliases\": {\"SCREENING (VISIT 1)\": \"enc_1\", \"SCREENING_(VISIT_1)\": \"enc_1\", \"CYCLE 1 DAY 1\": \"enc_2\", \"CYCLE_1_DAY_1\": \"enc_2\", \"CYCLE 1 DAY 8\": \"enc_3\", \"CYCLE_1_DAY_8\": \"enc_3\", \"CYCLE 1 DAY 15\": \"enc_4\", \"CYCLE_1_DAY_15\": \"enc_4\", \"CYCLE 2 DAY 1\": \"enc_5\", \"CYCLE_2_DAY_1\": \"enc_5\", \"CYCLE 2 DAY 8\": \"enc_6\", \"CYCLE_2_DAY_8\": \"enc_6\", \"CYCLE 2 DAY 15\": \"enc_7\", \"CYCLE_2_DAY_15\": \"enc_7\", \"CYCLE 3 AND BEYOND DAY 1\": \"enc_8\", \"CYCLE_3_AND_BEYOND_DAY_1\": \"enc_8\", \"CYCLE 3 AND BEYOND DAY 8\": \"enc_9\", \"CYCLE_3_AND_BEYOND_DAY_8\": \"enc_9\", \"CYCLE 3 AND BEYOND DAY 15\": \"enc_10\", \"CYCLE_3_AND_BEYOND_DAY_15\": \"enc_10\", \"DISCONTINUATION\": \"enc_11\", \"SAFETY FOLLOW-UP\": \"enc_12\", \"SAFETY_FOLLOW-UP\": \"enc_12\", \"FOLLOW UP VISITS\": \"enc_13\", \"FOLLOW_UP_VISITS\": \"enc_13\", \"SURVIVAL FOLLOW-UP\": \"enc_14\", \"SURVIVAL_FOLLOW-UP\": \"enc_14\"}}"
              },
              {
                "id": "2a40243f-2d90-49cb-a6f1-fae56a2fda70",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-promotionIssues",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Screening Window' reference remapped: 6deca4ba-c435-4e1b-80cf-8b52495f3364 \\u2192 anchor_inst_anchor_3\", \"affectedPath\": \"$.timings[?(@.id=='timing_1')]\"}, {\"severity\": \"warning\", \"category\": \"timing_reference_remapped\", \"message\": \"Timing 'Cycle 1 Day 1 Start' reference remapped: 6a019a7b-894c-482f-9cd7-b7a972ffb670 \\u2192 anchor_inst_anchor_1\", \"affectedPath\": \"$.timings[?(@.id=='timing_2')]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 82e34612-2631-4041-b038-9f6b472ec261\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 3f7fac8c-47cd-4da2-bda9-bd32a4c3bc03\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 109f2c67-489a-431d-ad15-e681c7c3da67\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: 19340055-5cc0-403a-90b5-b81867a86dd0\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}, {\"severity\": \"info\", \"category\": \"anchor_auto_created\", \"message\": \"Created anchor instance for missing reference: db1dd4ec-648f-4803-946c-677404f8306e\", \"affectedPath\": \"$.scheduleTimelines[0].instances[-1]\"}]"
              },
              {
                "id": "3ec9e25f-361b-40de-82d7-da76dcac547a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-timeAnchors",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"178375b0-7352-406c-a0c7-bda9b6beba08\", \"definition\": \"First administration of investigational product\", \"anchorType\": \"FirstDose\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"first \\ndose of study medication\"}, {\"id\": \"2171c3f8-370d-4959-86ff-fe7d4cb34e83\", \"definition\": \"Date of subject randomization\", \"anchorType\": \"Randomization\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"day of randomization\"}, {\"id\": \"3d9aa6c8-ec03-474e-aad7-e68d0ec8d259\", \"definition\": \"The start of the first dosing cycle for the assigned treatment\", \"anchorType\": \"Day1\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"After a screening phase of up to 28 days, eligible subjects will receive treatment beginning on Day 1 of each 3-week dosing cycle for pembrolizumab or investigator\\u2019s choice of paclitaxel (Days 1, 8, and 15 of every 28-day cycle), docetaxel (Day 1, every 21-day cycle), or irinotecan (Day 1, every 14-day cycle).\"}, {\"id\": \"eb3fe37e-6a63-493b-a6af-c62b7e0b09e0\", \"definition\": \"Screening visit\", \"anchorType\": \"Screening\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"screening visit\"}, {\"id\": \"7223cd0a-136c-48f3-9d95-330e81fa176c\", \"definition\": \"Informed consent obtained\", \"anchorType\": \"InformedConsent\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"informed \\nconsent\"}, {\"id\": \"f33623a6-3d03-4476-871f-5c0a664fc532\", \"definition\": \"procedure\", \"anchorType\": \"Custom\", \"timelineId\": null, \"dayValue\": 1, \"sourceText\": \"procedure\"}]"
              },
              {
                "id": "1bf3d90e-1b92-43b7-9a9e-a7809d5c2e85",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-repetitions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"d917a537-1033-4d8f-9b9f-5151bb69ca31\", \"type\": \"Daily\", \"interval\": \"P1D\", \"sourceText\": \"od\"}, {\"id\": \"69454cc4-0b0b-4e1c-b602-cf6c3d5d8dfd\", \"type\": \"Interval\", \"sourceText\": \"tid\"}, {\"id\": \"35c529bb-e95c-481f-815c-f55388e251c1\", \"type\": \"Cycle\", \"cycleLength\": \"P28D\", \"sourceText\": \"28-day \\ncycle\"}, {\"id\": \"3499f026-9810-43ff-b0f1-37f208d14477\", \"type\": \"Cycle\", \"cycleLength\": \"P21D\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"21-day cycle\"}, {\"id\": \"d2a7880e-17ff-476a-b9fd-140508fc6661\", \"type\": \"Cycle\", \"cycleLength\": \"P14D\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"14-day cycle\"}, {\"id\": \"512ad13a-ed5b-4a2e-8a7a-cb6d460c8798\", \"type\": \"Cycle\", \"cycleLength\": \"P3D\", \"sourceText\": \"repeated every 3 weeks\"}, {\"id\": \"345437b1-8062-47a4-b326-e5a522bc7fb3\", \"type\": \"Cycle\", \"sourceText\": \"Cycle 1 Day 1\"}, {\"id\": \"f1bcf3bf-0819-46f9-8439-ecbf9dd207a8\", \"type\": \"Cycle\", \"exitCondition\": \"Disease progression\", \"sourceText\": \"until progression\"}, {\"id\": \"585dd1a8-e7d0-46a1-86a8-ade3ba231898\", \"type\": \"Continuous\", \"sourceText\": \"screening phase\"}, {\"id\": \"6ef54dec-074c-4448-80da-d4e12bfb7c68\", \"type\": \"Continuous\", \"sourceText\": \"Treatment Period\"}, {\"id\": \"51a6bfbc-f312-4d25-8e7e-fce8bc71aeb6\", \"type\": \"Continuous\", \"sourceText\": \"120 days after\"}, {\"id\": \"9fb7b19a-8630-4c34-b826-bf6a6397ce68\", \"type\": \"Continuous\", \"sourceText\": \"180 days after\"}, {\"id\": \"78e0c935-badd-4c0f-8d00-19488d697064\", \"type\": \"Continuous\", \"sourceText\": \"3 days after\"}, {\"id\": \"8d6ef5ed-317a-48bd-928e-14de165dcdfd\", \"type\": \"Continuous\", \"sourceText\": \"3 days before\"}, {\"id\": \"8d90ec92-1e41-44b2-bc7f-b038265a661c\", \"type\": \"Continuous\", \"sourceText\": \"30 days before\"}, {\"id\": \"b98003b9-ca8f-4885-b1a8-8ef32f36df48\", \"type\": \"Continuous\", \"sourceText\": \"30 days after\"}, {\"id\": \"07dd3ae9-2f18-445c-83d2-4a8a559c2e6c\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P21D\", \"minObservations\": 1, \"exitCondition\": \"End of treatment or disease progression\", \"sourceText\": \"Arm 1: Pembrolizumab (MK-3475) 200 mg IV every 3-weeks\"}, {\"id\": \"32d0fc86-1720-4cef-b176-1e36c8fd47a1\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P28D\", \"minObservations\": 3, \"exitCondition\": \"End of treatment or disease progression\", \"sourceText\": \"Paclitaxel 80-100 mg/m2 on Days 1, 8, and 15 of every 28-day (4-week) cycle\"}, {\"id\": \"330fd70d-fcf0-4f11-a95b-e7212a9b7ece\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P21D\", \"minObservations\": 1, \"exitCondition\": \"End of treatment or disease progression\", \"sourceText\": \"Docetaxel 75 mg/m2 on Day 1 of every 21-day (3-week) cycle\"}, {\"id\": \"1f5176b3-8c14-4d1f-befd-6af9be42a551\", \"type\": \"Cycle\", \"startOffset\": \"P0D\", \"interval\": \"P14D\", \"minObservations\": 1, \"exitCondition\": \"End of treatment or disease progression\", \"sourceText\": \"Irinotecan 180 mg/m2 on Day 1 of every 14-day (2-week) cycle\"}, {\"id\": \"a1fe965a-ea39-459b-8bd3-85717b2f7680\", \"type\": \"Continuous\", \"startOffset\": \"-P28D\", \"endOffset\": \"P0D\", \"interval\": \"P28D\", \"minObservations\": 1, \"exitCondition\": \"Completion of eligibility verification\", \"sourceText\": \"After a screening phase of up to 28 days, eligible subjects will receive treatment beginning on Day 1\"}]"
              },
              {
                "id": "be343fee-9d33-498d-8d6e-a6b45d6175c6",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-traversalConstraints",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"0eade01d-8b33-4a2f-b770-9e62dcd8dc99\", \"requiredSequence\": [\"epoch_1\", \"epoch_2\", \"epoch_4\", \"epoch_4\", \"epoch_4\"], \"allowEarlyExit\": true, \"exitEpochIds\": [], \"mandatoryVisits\": [\"enc_1\", \"enc_12\", \"enc_2\", \"enc_14\", \"enc_1\"], \"sourceText\": \"[{'condition': 'Subject achieves Complete Response (CR) and meets criteria for discontinuation', 'path': ['DISCONTINUATION_AFTER_CR', 'FOLLOW_UP']}, {'condition': 'Subject experiences disease progression after initial response', 'path': ['SECOND_COURSE_PHASE', 'RETREATMENT_WITH_PEMBROLIZUMAB']}, {'condition': 'Subject experiences AE requiring discontinuation', 'path': ['WITHDRAWAL_DISCONTINUATION', 'SAFETY_FOLLOW_UP']}]\"}]"
              },
              {
                "id": "93be9ef2-f2d1-4106-86e8-ff90282cb40f",
                "url": "https://protocol2usdm.io/extensions/x-footnoteConditions",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"445ac988-6abe-4ad1-bb48-855e30e192fe\", \"conditionType\": \"timing_after\", \"text\": \"a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone.\", \"footnoteId\": \"9fbaf14c-c6ff-4982-96b2-d46af891d89c\", \"sourceText\": \"a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately\", \"appliesToActivityIds\": [\"442298d8-8831-4a89-ae30-6befcf07fb98\", \"138de4b1-91ac-4e23-ae69-1f18013ebe17\", \"2058d9a8-059b-4538-897a-a4fa84b0875d\"]}, {\"id\": \"91ffc8d1-af8a-4519-90a2-590bb7e05469\", \"conditionType\": \"timing_after\", \"text\": \"b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of pembrolizumab may be administered up to 3 days after randomization.\", \"footnoteId\": \"d73796f1-8344-4a20-843e-44cbf53ceea0\", \"sourceText\": \"b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of pembrolizumab may\", \"appliesToActivityIds\": [\"138de4b1-91ac-4e23-ae69-1f18013ebe17\"]}, {\"id\": \"d697f480-8563-4479-9246-57f4f0d65b1e\", \"conditionType\": \"timing_after\", \"text\": \"c. SAEs will be followed through 90 days following cessation of treatment, or 30 days if the subject initiates new anticancer therapy.\", \"footnoteId\": \"9595ccf1-4a70-4faa-a907-005b3c86c715\", \"sourceText\": \"c. SAEs will be followed through 90 days following cessation of treatment, or 30 days if the subject\", \"appliesToActivityIds\": [\"442298d8-8831-4a89-ae30-6befcf07fb98\", \"138de4b1-91ac-4e23-ae69-1f18013ebe17\", \"39578a9d-9d32-4cbd-8ae2-727e40d59770\"]}, {\"id\": \"b8559135-0793-4fb0-8f7c-936c328f233b\", \"conditionType\": \"procedure_timepoints\", \"text\": \"d. Height will be measured at Visit 1 only.\", \"footnoteId\": \"e29e2ef4-be1e-45b4-ab32-dca995127be5\", \"sourceText\": \"d. Height will be measured at Visit 1 only.\"}, {\"id\": \"6d860472-d595-418b-84ee-490b237b1ced\", \"conditionType\": \"timing_before\", \"text\": \"e. ECOG Performance Status and Laboratory tests for screening are to be performed within 3 days prior to the first dose.\", \"footnoteId\": \"5981bda1-5ff5-4aae-b68d-6629aaad6cef\", \"sourceText\": \"e. ECOG Performance Status and Laboratory tests for screening are to be performed within 3 days prio\", \"appliesToActivityIds\": [\"f25386d8-39e5-4b65-9ae6-a85faf5387cf\", \"442298d8-8831-4a89-ae30-6befcf07fb98\", \"8bff46ca-00a4-4f28-afea-b9239dbe5da6\", \"cc93b7e9-62e0-4778-9978-630642c114c4\", \"f9d3c0d9-a4d8-49e4-92b0-01765ff66432\"]}, {\"id\": \"33c11a95-6b4a-44ed-9723-ee1db69c15bd\", \"conditionType\": \"timing_after\", \"text\": \"f. PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle 7, PROs are to be performed every 3 cycles.\", \"footnoteId\": \"345cb040-a8a9-4a34-80ee-a6281fdef302\", \"sourceText\": \"f. PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle\", \"appliesToActivityIds\": [\"57f57586-6635-4506-98a2-546d6a30c0b1\", \"f25386d8-39e5-4b65-9ae6-a85faf5387cf\"]}, {\"id\": \"99e1538d-b5a2-4c5a-bbae-8c4e84172d6a\", \"conditionType\": \"timing_before\", \"text\": \"g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle.\", \"footnoteId\": \"c8f835f0-f2cc-466b-9dd8-266b72d87701\", \"structuredCondition\": \"timing.before(day 1 of each treatment cycle., PT72M)\", \"timingConstraint\": \"PT72H\", \"sourceText\": \"g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 7\", \"appliesToActivityIds\": [\"8bff46ca-00a4-4f28-afea-b9239dbe5da6\", \"138de4b1-91ac-4e23-ae69-1f18013ebe17\", \"f9d3c0d9-a4d8-49e4-92b0-01765ff66432\", \"f25386d8-39e5-4b65-9ae6-a85faf5387cf\"]}, {\"id\": \"254ff8ea-7bd2-45da-b258-9717ec01ce43\", \"conditionType\": \"general\", \"text\": \"h. Urinalysis and thyroid function tests are performed Day 1 of every other cycle. CBC and Chemistry to be performed every cycle.\", \"footnoteId\": \"5fbe7e5b-b4aa-4197-be27-224b0880697d\", \"sourceText\": \"h. Urinalysis and thyroid function tests are performed Day 1 of every other cycle. CBC and Chemistry\", \"appliesToActivityIds\": [\"43393633-2657-4df2-b7de-274471bce080\", \"4b2e7f3a-fc7a-4bcd-bc43-4676966450f9\", \"f9d3c0d9-a4d8-49e4-92b0-01765ff66432\", \"f25386d8-39e5-4b65-9ae6-a85faf5387cf\"]}, {\"id\": \"317d99da-b0af-4c3f-92e5-1e75202a4e71\", \"conditionType\": \"general\", \"text\": \"i. Detailed instructions for the collection and management of specimens are provided in the Central Lab Manual.\", \"footnoteId\": \"bd523f53-0682-47aa-9264-8f41f6ce05ca\", \"sourceText\": \"i. Detailed instructions for the collection and management of specimens are provided in the Central \", \"appliesToActivityIds\": [\"7bdd2ec9-6ed9-41bd-b864-a08cf30c5bd2\", \"2058d9a8-059b-4538-897a-a4fa84b0875d\"]}, {\"id\": \"8317c0b6-dcca-4548-99b9-576998c5e784\", \"conditionType\": \"timing_at\", \"text\": \"j. Whole blood samples for correlative studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3.\", \"footnoteId\": \"39938326-fb6b-4101-be24-c22f522c15a8\", \"sourceText\": \"j. Whole blood samples for correlative studies (DNA and RNA) should be collected pre-dose on Day 1 o\", \"appliesToActivityIds\": [\"512060d9-eea2-40cc-8e8f-7a2daadc779f\", \"706e29cf-3fa9-4154-866e-6298967d6cc0\"]}, {\"id\": \"e9b1bc16-a0b8-405a-b663-bde5fcb01c2b\", \"conditionType\": \"general\", \"text\": \"k. Newly-obtained tissue is preferred (no intervening treatment involving the site of tissue biopsy once tissue biopsy is obtained).\", \"footnoteId\": \"4a8d8f56-1674-4ac2-8932-765c1aa603bc\", \"sourceText\": \"k. Newly-obtained tissue is preferred (no intervening treatment involving the site of tissue biopsy \", \"appliesToActivityIds\": [\"138de4b1-91ac-4e23-ae69-1f18013ebe17\", \"7bdd2ec9-6ed9-41bd-b864-a08cf30c5bd2\", \"71cc27da-22ef-4013-9416-84ee3b7295a4\"]}, {\"id\": \"78c5f395-2c18-4102-8c0f-25543b432195\", \"conditionType\": \"general\", \"text\": \"l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment.\", \"footnoteId\": \"e347f6d1-c342-41fc-9ccb-4e5cf1c23b8c\", \"sourceText\": \"l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of \", \"appliesToActivityIds\": [\"896dca02-a1b6-4bbc-b140-e4dd5d2dbafa\", \"7bdd2ec9-6ed9-41bd-b864-a08cf30c5bd2\", \"c04467fa-c66e-4fe5-96e4-096b5982718a\"]}, {\"id\": \"1c5b0c16-3f0c-4631-a4f5-98f83fb9647a\", \"conditionType\": \"timing_before\", \"text\": \"m. Screening tumor imaging will be performed within 14 days prior to randomization.\", \"footnoteId\": \"530e7b5a-f3c1-4809-95c5-ffe53a695108\", \"sourceText\": \"m. Screening tumor imaging will be performed within 14 days prior to randomization.\", \"appliesToActivityIds\": [\"8bff46ca-00a4-4f28-afea-b9239dbe5da6\", \"7bdd2ec9-6ed9-41bd-b864-a08cf30c5bd2\", \"04432ef2-90f3-450a-b914-fc58628dfc7d\", \"f25386d8-39e5-4b65-9ae6-a85faf5387cf\"]}, {\"id\": \"8885762c-fc17-4690-b946-63548e1635ea\", \"conditionType\": \"general\", \"text\": \"n. The first on-study imaging time point will be performed at 9 weeks (63 days \\u00b1 7 days) calculated from the date of allocation.\", \"footnoteId\": \"ae772cc5-40d9-4424-a5b2-c76cb14662ae\", \"sourceText\": \"n. The first on-study imaging time point will be performed at 9 weeks (63 days \\u00b1 7 days) calculated \", \"appliesToActivityIds\": [\"04432ef2-90f3-450a-b914-fc58628dfc7d\", \"f25386d8-39e5-4b65-9ae6-a85faf5387cf\"]}]"
              },
              {
                "id": "0b103094-6836-47b9-b3c9-ae74afd96889",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-endpointAlgorithms",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"b04cb60b-7603-49c2-b87c-bbf64d4916d6\", \"name\": \"Primary: Overall Survival (OS)\", \"endpointType\": \"Primary\", \"inputs\": [\"Date of Death\", \"Date of Randomization\"], \"timeWindow\": {\"reference\": \"Randomization\", \"duration\": \"Until death from any cause\"}, \"algorithm\": \"Date of Death - Date of Randomization\", \"successCriteria\": \"Statistically significant increase in time to death compared to control\", \"sourceText\": \"Overall Survival (OS)\"}, {\"id\": \"74d8e4aa-546b-42e5-bac7-025fa75cb920\", \"name\": \"Secondary: Progression-Free Survival (PFS)\", \"endpointType\": \"Secondary\", \"inputs\": [\"Date of Disease Progression\", \"Date of Death\", \"Date of Randomization\"], \"timeWindow\": {\"reference\": \"Randomization\", \"duration\": \"Until first instance of progression or death\"}, \"algorithm\": \"min(Date of Disease Progression, Date of Death) - Date of Randomization\", \"successCriteria\": \"Statistically significant increase in time to progression or death compared to control\", \"sourceText\": \"Progression-Free Survival (PFS)\"}, {\"id\": \"a836308e-c6d9-4a33-bb01-a9acfb0a27ea\", \"name\": \"Secondary: Objective Response Rate (ORR)\", \"endpointType\": \"Secondary\", \"inputs\": [\"Complete Response (CR) count\", \"Partial Response (PR) count\", \"Total number of subjects\"], \"timeWindow\": {\"reference\": \"Baseline\", \"duration\": \"During trial treatment period\"}, \"algorithm\": \"(Number of subjects with CR + Number of subjects with PR) / Total number of subjects\", \"successCriteria\": \"Proportion of subjects achieving CR or PR based on RECIST 1.1\", \"sourceText\": \"Objective Response Rate (ORR)\"}]"
              },
              {
                "id": "2edbf038-0dfb-46ad-8dd7-8fedcff48302",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-derivedVariables",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"285576b4-a250-496e-b96e-209717a0cd80\", \"name\": \"Percent Change in Body Surface Area\", \"variableType\": \"PercentChange\", \"sourceVariables\": [\"Body Surface Area\"], \"derivationRule\": \"((Current BSA - Baseline BSA) / Baseline BSA) * 100\", \"baselineDefinition\": \"Body surface area measured at baseline prior to first dose\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Prior to each dosing cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"%\"}, {\"id\": \"a771d538-1f83-4bc6-bcce-63983439e0ef\", \"name\": \"Recalculated Paclitaxel Dose\", \"variableType\": \"Custom\", \"sourceVariables\": [\"Body Surface Area\", \"Baseline Body Surface Area\"], \"derivationRule\": \"If BSA change from baseline or last recalculation is >= 10%, dose = (80-100 mg/m2 * current BSA). If < 10%, recalculation is optional.\", \"baselineDefinition\": \"Body surface area at baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Days 1, 8, and 15 of each 28-day cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"mg\"}, {\"id\": \"40240e2d-3863-45f0-b3c4-a54470cdfd18\", \"name\": \"Recalculated Docetaxel Dose\", \"variableType\": \"Custom\", \"sourceVariables\": [\"Body Surface Area\", \"Baseline Body Surface Area\"], \"derivationRule\": \"If BSA change from baseline or last recalculation is >= 10%, dose = (75 mg/m2 * current BSA). If < 10%, recalculation is optional.\", \"baselineDefinition\": \"Body surface area at baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Day 1 of each 21-day cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"mg\"}, {\"id\": \"33e85047-7794-4b1b-815e-670ee349744b\", \"name\": \"Recalculated Irinotecan Dose\", \"variableType\": \"Custom\", \"sourceVariables\": [\"Body Surface Area\", \"Baseline Body Surface Area\"], \"derivationRule\": \"If BSA change from baseline or last recalculation is >= 10%, dose = (180 mg/m2 * current BSA). If < 10%, recalculation is optional.\", \"baselineDefinition\": \"Body surface area at baseline\", \"baselineVisit\": \"Baseline\", \"analysisWindow\": \"Day 1 of each 14-day cycle\", \"imputationRule\": \"Not specified\", \"unit\": \"mg\"}]"
              },
              {
                "id": "4ecb7834-cb33-4fcc-b9a1-8485918b34f3",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-stateMachine",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"9ba84a36-6d9e-489a-a0b8-f5ee1d200b0d\", \"initialState\": \"Screening\", \"terminalStates\": [\"Early Termination\", \"Completed\"], \"states\": [\"Screening\", \"Initial Treatment Phase\", \"Post Treatment Follow Up\", \"Safety Follow Up\", \"Survival Follow Up\", \"Early Termination\"], \"transitions\": [{\"fromState\": \"Screening\", \"toState\": \"Initial Treatment Phase\", \"trigger\": \"Progress to Initial Treatment Phase\"}, {\"fromState\": \"Initial Treatment Phase\", \"toState\": \"Post Treatment Follow Up\", \"trigger\": \"Progress to Post Treatment Follow Up\"}, {\"fromState\": \"Post Treatment Follow Up\", \"toState\": \"Safety Follow Up\", \"trigger\": \"Progress to Safety Follow Up\"}, {\"fromState\": \"Safety Follow Up\", \"toState\": \"Survival Follow Up\", \"trigger\": \"Progress to Survival Follow Up\"}, {\"fromState\": \"Initial Treatment Phase\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}, {\"fromState\": \"Post Treatment Follow Up\", \"toState\": \"Early Termination\", \"trigger\": \"Subject exits to Early Termination\"}], \"epochIds\": {\"Screening\": \"SCREENING\", \"Initial Treatment Phase\": \"INITIAL_TREATMENT_PHASE\", \"Post Treatment Follow Up\": \"POST_TREATMENT_FOLLOW_UP\", \"Safety Follow Up\": \"SAFETY_FOLLOW_UP\", \"Survival Follow Up\": \"SURVIVAL_FOLLOW_UP\", \"Early Termination\": \"EARLY_TERMINATION\"}}"
              },
              {
                "id": "2bb661b7-d66f-42ea-8f99-42e7f6a0c365",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-dosingRegimens",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"ae312478-7326-48a5-97ad-54a5d48f7f2e\", \"treatmentName\": \"Docetaxel\", \"frequency\": \"QD\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 75.0, \"unit\": \"mg\"}, {\"amount\": 200.0, \"unit\": \"mg\"}, {\"amount\": 180.0, \"unit\": \"mg\"}, {\"amount\": 100.0, \"unit\": \"mg\"}], \"doseModifications\": [\"Dose modification for toxicity as per section 5.2.1.2.2\"], \"sourceText\": \"pen-label Treatment Groups Arm 1: Pembrolizumab (MK-3475) 200 mg IV every 3-weeks Arm 2: Investigator\\u2019s choice of: - Paclitaxel 80-100 mg/m2 on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR - D\"}, {\"id\": \"b5c2cf7b-77b9-49b1-8f6e-0299bc03b9f1\", \"treatmentName\": \"Irinotecan\", \"frequency\": \"QD\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 180.0, \"unit\": \"mg\"}, {\"amount\": 75.0, \"unit\": \"mg\"}, {\"amount\": 100.0, \"unit\": \"mg\"}], \"doseModifications\": [\"Dose modification for toxicity as per section 5.2.1.2.2\"], \"sourceText\": \"IV every 3-weeks Arm 2: Investigator\\u2019s choice of: - Paclitaxel 80-100 mg/m2 on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR - Docetaxel 75 mg/m2 on Day 1 of every 21-day (3-week) cycle, OR - I\"}, {\"id\": \"2d084ed1-4792-4448-adc6-69f1ed6da9bf\", \"treatmentName\": \"Pembrolizumab\", \"frequency\": \"Q3W\", \"route\": \"Oral\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 200.0, \"unit\": \"mg\"}], \"durationDescription\": \"3 weeks\", \"sourceText\": \"pe I adenocarcinoma of the EGJ who have progressed on one previous line of standard therapy. 1) Objective: to compare OS in subjects with squamous cell carcinoma of the esophagus. Hypothesis (H1): Pem\"}, {\"id\": \"2e8a668b-a236-4ee7-8f68-ffb40e2b2f89\", \"treatmentName\": \"Pembrolizumab (MK-3475)\", \"frequency\": \"Q3W\", \"route\": \"IV\", \"startDay\": 1, \"doseLevels\": [{\"amount\": 200.0, \"unit\": \"mg\", \"description\": \"Fixed dose\"}], \"durationDescription\": \"Until progression or unacceptable toxicity\", \"doseModifications\": [\"Withhold, Treat, or Discontinue based on Immune-Related Events\"]}, {\"id\": \"30f7abdc-1e12-49d1-a5b7-758d77b30b6f\", \"treatmentName\": \"Paclitaxel\", \"frequency\": \"QW\", \"route\": \"IV\", \"startDay\": 1, \"doseModifications\": [\"Dose modification for toxicity as per section 5.2.1.2.2\"]}]"
              },
              {
                "id": "8c9f1668-2a22-4971-b8d8-877c8a234023",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-visitWindows",
                "instanceType": "ExtensionAttribute",
                "valueString": "[{\"id\": \"dfddeafc-7a5c-4a50-acde-27dcfa16a13b\", \"visitName\": \"Screening\", \"targetDay\": -14, \"windowBefore\": 7, \"windowAfter\": 28, \"isRequired\": true, \"visitNumber\": 1, \"epoch\": \"Screening\", \"sourceText\": \"Screening...................................................................................................... 89 Treatment Period.....................................................................\"}, {\"id\": \"38039900-900c-4161-a8da-5eb82ff1bff3\", \"visitName\": \"Early Termination\", \"targetDay\": null, \"windowBefore\": 0, \"windowAfter\": 0, \"isRequired\": true, \"visitNumber\": 2, \"sourceText\": \"Safety Follow-up Visits ........................................................................ 91 7.1.6.3.2 Follow-up Visits .........................................................................\"}, {\"id\": \"a8bfae57-47f2-48d4-bd32-9c3b9e477717\", \"visitName\": \"end of treatment\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 3, \"sourceText\": \"After the end of treatment, each subject will be followed for 30 days for adverse event monitoring. Serious adverse events (SAE) will be collected for 90 days after the end of treatment or for 30 days\"}, {\"id\": \"17b0cfec-fcb7-4436-ba47-c070295395c8\", \"visitName\": \"Visit 4\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 4, \"sourceText\": \"(CTCAEv4.0) Action With Pembrolizumab\"}, {\"id\": \"e2b4a50c-cef1-4ef0-9dc4-c2eb103d6394\", \"visitName\": \"baseline\", \"targetDay\": 0, \"windowBefore\": 1, \"windowAfter\": 1, \"isRequired\": true, \"visitNumber\": 5, \"sourceText\": \"baseline or is stable) Grade 3 or 4 Permanently\"}, {\"id\": \"d1f38b5d-0438-46a1-b96e-53b19261732d\", \"visitName\": \"Visit 1\", \"targetDay\": null, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 6, \"sourceText\": \"(Visit 1) 1 2\"}, {\"id\": \"835d108c-7e56-4e97-a006-704f93ea990d\", \"visitName\": \"Survival Follow-up\", \"targetDay\": null, \"windowBefore\": null, \"windowAfter\": null, \"isRequired\": true, \"visitNumber\": 5, \"epoch\": \"Post-Trial Visits\"}, {\"id\": \"86a9eff2-86d9-4524-9c72-906d670f10cc\", \"visitName\": \"randomization\", \"targetDay\": 1, \"windowBefore\": 3, \"windowAfter\": 3, \"isRequired\": true, \"visitNumber\": 9, \"sourceText\": \"Trial treatment for Cycle 1 should begin within 3 days of randomization. However, every effort should be made to begin trial treatment on day of randomization. All supplies indicated in Table 2 above \"}, {\"id\": \"8566b8eb-620e-4ecf-adc4-0801e4415b2d\", \"visitName\": \"Day 15\", \"targetDay\": 15, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 10, \"sourceText\": \"2-Day 15, Cycle 3-Day 8, Cycle 4-Day 1, Cycle 5-Day 15, Cycle 7-Day 22, Cycle 10-Day 1, and Cycle 12-Day 8. PROs are to be performed up to a year or End of Treatment, whichever comes first, and the 30\"}, {\"id\": \"c8149fed-edd2-4371-a1a1-965fa6569478\", \"visitName\": \"Week 18\", \"targetDay\": 120, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 11, \"targetWeek\": 18, \"sourceText\": \"and Cycle 7. After Cycle 7 (Week 18), PROs are to be performed every 3 cycles (e.g., Week 27, Week 36, Week 45). PROs are to be performed up to a year or End of Treatment, whichever comes first, and t\"}, {\"id\": \"b294ad3e-8d3c-4762-adba-f21d196b6c72\", \"visitName\": \"Follow-up\", \"targetDay\": 365, \"windowBefore\": 7, \"windowAfter\": 7, \"isRequired\": true, \"visitNumber\": 12, \"epoch\": \"Post-Trial Visits\", \"sourceText\": \"Lost to Follow-up.................................................................................. 88 7.1.5.2 Blinding/Unblinding .....................................................................\"}]"
              },
              {
                "id": "6e52724d-49af-452a-9b9c-c948d39f5b6a",
                "url": "https://protocol2usdm.io/extensions/x-executionModel-randomizationScheme",
                "instanceType": "ExtensionAttribute",
                "valueString": "{\"id\": \"77bd5e80-7039-4a53-9ce6-1895363336b0\", \"ratio\": \"1:1\", \"method\": \"Stratified randomization\", \"centralRandomization\": true, \"stratificationFactors\": [{\"id\": \"df1ac130-cd58-4b31-ab8e-f2214913f5e7\", \"name\": \"Region\", \"categories\": [\"North America\", \"Europe\", \"Asia\", \"Rest of World\"], \"isBlocking\": false, \"sourceText\": \"tumor histology and by \\ngeographic region (see section 5\"}, {\"id\": \"f2df97e0-ddb5-4d5a-8cb8-865522a49a92\", \"name\": \"Tumor histology\", \"categories\": [\"Adenocarcinoma\", \"Squamous cell carcinoma\"], \"isBlocking\": false}, {\"id\": \"cc4fca25-87c0-4716-9f73-e1ee495db623\", \"name\": \"Geographic region\", \"categories\": null, \"isBlocking\": false}], \"sourceText\": \"Product:  MK-3475 \\n3\\nProtocol/Amendment No.: 181-06 \\nMK-3475-181-06 Final Protocol\\n25-Jun-2021\\nConfidential\\n4.2.3.5.1\\nBiomarker Research for Primary Objectives........................................ \"}"
              },
              {
                "id": "6e1dd1c6-2fb4-4348-bb76-82c7c66ee599",
                "url": "https://protocol2usdm.io/extensions/x-soaFootnotes",
                "valueString": "[\"a. After centrally verified PD, or the start of new anticancer treatment; contacts are approximately every 9 weeks by telephone.\", \"b. Cycle 1 treatment must be given within 3 days of allocation. Trial treatment of pembrolizumab may be administered up to 3 days after randomization.\", \"c. SAEs will be followed through 90 days following cessation of treatment, or 30 days if the subject initiates new anticancer therapy.\", \"d. Height will be measured at Visit 1 only.\", \"e. ECOG Performance Status and Laboratory tests for screening are to be performed within 3 days prior to the first dose.\", \"f. PROs are to be performed at Cycle 1, Cycle 2, Cycle 3, Cycle 4, Cycle 5, and Cycle 7. After Cycle 7, PROs are to be performed every 3 cycles.\", \"g. For women of reproductive potential, a urine or serum pregnancy test should be performed within 72 hours prior to Day 1 of each treatment cycle.\", \"h. Urinalysis and thyroid function tests are performed Day 1 of every other cycle. CBC and Chemistry to be performed every cycle.\", \"i. Detailed instructions for the collection and management of specimens are provided in the Central Lab Manual.\", \"j. Whole blood samples for correlative studies (DNA and RNA) should be collected pre-dose on Day 1 of Cycle 1, Cycle 2, and Cycle 3.\", \"k. Newly-obtained tissue is preferred (no intervening treatment involving the site of tissue biopsy once tissue biopsy is obtained).\", \"l. Archival tumor tissue will also be requested (where available) to assess the clinical utility of immune-related GEP assessment.\", \"m. Screening tumor imaging will be performed within 14 days prior to randomization.\", \"n. The first on-study imaging time point will be performed at 9 weeks (63 days \\u00b1 7 days) calculated from the date of allocation.\"]",
                "instanceType": "ExtensionAttribute"
              }
            ],
            "administrations": [
              {
                "id": "e0ae2958-1427-44f6-b24e-7dd8f5bda8f5",
                "name": "Docetaxel Administration",
                "instanceType": "Administration",
                "dose": "75.0 mg / 200.0 mg / 180.0 mg / 100.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "b5168561-ccb7-4cd6-bf73-eeb7bd12d298",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "description": "pen-label Treatment Groups Arm 1: Pembrolizumab (MK-3475) 200 mg IV every 3-weeks Arm 2: Investigator’s choice of: - Paclitaxel 80-100 mg/m2 on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR - D"
              },
              {
                "id": "592b390b-fbb3-447e-a9f6-f2624436d4db",
                "name": "Irinotecan Administration",
                "instanceType": "Administration",
                "dose": "180.0 mg / 75.0 mg / 100.0 mg",
                "doseFrequency": "QD",
                "route": {
                  "id": "97364656-a80c-4fba-9232-8c40b65682b9",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "description": "IV every 3-weeks Arm 2: Investigator’s choice of: - Paclitaxel 80-100 mg/m2 on Days 1, 8, and 15 of every 28-day (4-week) cycle, OR - Docetaxel 75 mg/m2 on Day 1 of every 21-day (3-week) cycle, OR - I"
              },
              {
                "id": "a4033bfb-56d6-4894-82cb-51339b5359aa",
                "name": "Pembrolizumab Administration",
                "instanceType": "Administration",
                "dose": "200.0 mg",
                "doseFrequency": "Q3W",
                "route": {
                  "id": "161aa0c7-2621-47ea-b7bc-b7b3b1773a62",
                  "code": "Oral",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Oral",
                  "instanceType": "Code"
                },
                "duration": "3 weeks",
                "description": "pe I adenocarcinoma of the EGJ who have progressed on one previous line of standard therapy. 1) Objective: to compare OS in subjects with squamous cell carcinoma of the esophagus. Hypothesis (H1): Pem"
              },
              {
                "id": "a42db1b0-eea3-4b3b-9c64-afd25a7267fc",
                "name": "Pembrolizumab (MK-3475) Administration",
                "instanceType": "Administration",
                "dose": "200.0 mg",
                "doseFrequency": "Q3W",
                "route": {
                  "id": "11467cee-95fb-411f-bf10-81041afcbff4",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                },
                "duration": "Until progression or unacceptable toxicity"
              },
              {
                "id": "d88f054a-794b-48a2-88de-2e81450901ff",
                "name": "Paclitaxel Administration",
                "instanceType": "Administration",
                "doseFrequency": "QW",
                "route": {
                  "id": "5c8ec44f-e04f-401b-ac86-662cb190b58b",
                  "code": "IV",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "IV",
                  "instanceType": "Code"
                }
              }
            ]
          }
        ],
        "titles": [
          {
            "id": "af80eb3c-0d1f-48c5-a71e-ef3d2776aa29",
            "text": "A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)",
            "type": {
              "id": "ef4a4225-ab12-45ae-a441-1676daaa2017",
              "code": "Official Study Title",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Official Study Title",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          },
          {
            "id": "27db7872-7cca-4c80-8924-e0de832496e1",
            "text": "KEYNOTE-181",
            "type": {
              "id": "a29a72ff-f916-4003-9f39-363d0f139ab0",
              "code": "Study Acronym",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Acronym",
              "instanceType": "Code"
            },
            "instanceType": "StudyTitle"
          }
        ],
        "studyIdentifiers": [
          {
            "id": "a0ff2954-2734-4d91-8400-43209081823a",
            "text": "NCT02564263",
            "instanceType": "StudyIdentifier",
            "scopeId": "751411b2-25e4-45cf-ae4f-3d58b6d5b2ea",
            "type": {
              "code": "C172240",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinicaltrials.gov Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "52ff9ee1-d273-417d-8109-ea412f27f882",
            "text": "181-06",
            "instanceType": "StudyIdentifier",
            "scopeId": "690a7640-e71d-4b0c-879b-626a859b3d05",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "45baba83-deae-40ca-93cf-ed857ccabeb4",
            "text": "MK-3475-181-06",
            "instanceType": "StudyIdentifier",
            "scopeId": "690a7640-e71d-4b0c-879b-626a859b3d05",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "5be9465c-02fd-4c46-946a-4f69bf3d84af",
            "text": "2015-002782-32",
            "instanceType": "StudyIdentifier",
            "scopeId": "a06709f0-76c0-4d23-bf1d-35b1295950c8",
            "type": {
              "code": "C98714",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Clinical Trial Registry Identifier",
              "instanceType": "Code"
            }
          },
          {
            "id": "910fb15b-f43b-4e71-b41f-85c270c512ee",
            "text": "123,482",
            "instanceType": "StudyIdentifier",
            "scopeId": "8d9e7d4a-57c1-4f36-aebf-61bffc36926c",
            "type": {
              "code": "C132351",
              "codeSystem": "http://www.cdisc.org",
              "codeSystemVersion": "2024-09-27",
              "decode": "Sponsor Protocol Identifier",
              "instanceType": "Code"
            }
          }
        ],
        "organizations": [
          {
            "id": "690a7640-e71d-4b0c-879b-626a859b3d05",
            "name": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",
            "type": {
              "id": "2b631aba-2e80-4728-8392-be6f8b6b8975",
              "code": "C54086",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Pharmaceutical Company",
              "instanceType": "Code"
            },
            "identifier": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "751411b2-25e4-45cf-ae4f-3d58b6d5b2ea",
            "name": "ClinicalTrials.gov",
            "type": {
              "id": "ea19e16d-e4ea-4ab7-8235-db629da2c44c",
              "code": "C19326",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Healthcare Facility",
              "instanceType": "Code"
            },
            "identifier": "ClinicalTrials.gov",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          },
          {
            "id": "8d9e7d4a-57c1-4f36-aebf-61bffc36926c",
            "name": "FDA",
            "type": {
              "id": "7e89979e-aa0a-42a3-8505-2ddb87e29dbc",
              "code": "C25461",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Regulatory Agency",
              "instanceType": "Code"
            },
            "identifier": "FDA",
            "identifierScheme": "DUNS",
            "instanceType": "Organization"
          }
        ],
        "studyPhase": {
          "id": "d6ef18cb-caac-44ee-b5f0-d36383b718a4",
          "code": "Phase3",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Phase3",
          "instanceType": "Code"
        },
        "eligibilityCriterionItems": [
          {
            "id": "b69dfbfb-c942-411c-8925-0a72791b4a28",
            "name": "Informed Consent",
            "text": "Be willing and able to provide documented informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "4d406544-d47b-46fb-b8c2-b8592673d506",
            "name": "Age Requirement",
            "text": "Be ≥ 18 years of age on the day of providing documented informed consent (or acceptable age according to local regulations, whichever is older).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ef00e6f2-abc8-4d49-a28d-f8a3a0fdad52",
            "name": "Diagnosis Confirmation",
            "text": "Have histologically or cytologically-confirmed diagnosis of adenocarcinoma or SCC of the esophagus or Siewert type I adenocarcinoma of the EGJ (defined as adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ). a. Subjects with Siewert type 1 adenocarcinoma of the EGJ with HER-2/neu negative tumors are eligible. Subjects with HER2/neu positive tumors, or those with an unknown tumor status, need to match the following: i. If HER2/neu positive, subject must have documentation of disease progression on a prior line of therapy containing trastuzumab. ii. Subjects with unknown status must have their HER2/neu status determined locally. If HER2/neu negative, the subject will be eligible. If HER2/neu positive, the subject must have documentation of disease progression on a prior line of therapy containing trastuzumab.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "05984ec7-36d9-4d1e-ae0c-b8a36ca31fef",
            "name": "Disease Status",
            "text": "Have metastatic disease or locally advanced, unresectable disease. Subjects with direct invasion into adjacent organs such as the aorta or trachea (T4b disease) should be closely evaluated for bleeding risk prior to enrollment and a sponsor consultation before enrollment is required.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fe64a7ad-fdc7-4de2-9028-50f86cd840aa",
            "name": "Life Expectancy",
            "text": "Have a life expectancy of greater than 3 months.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c201aea3-0569-4948-ba22-420b0a69414d",
            "name": "Measurable Disease",
            "text": "Have measurable disease based on RECIST 1.1 as determined by local site investigator/radiology assessment. A lesion(s) situated in a previously irradiated area can be considered a target lesion(s) if progression has been demonstrated and the lesion(s) is considered measurable per RECIST 1.1 criteria. Note: The same image acquisition and processing parameters should be used throughout the study for a given subject.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "a29b183b-2fd1-4ed4-81a9-0f4c6060abd5",
            "name": "Performance Status",
            "text": "Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "e91b772c-7c54-402c-a118-a74ef6ed30c0",
            "name": "Prior Therapy Progression",
            "text": "Have experienced documented radiographic or clinical disease progression on one previous line of standard therapy. This study will only include second-line subjects. Second-line subjects are defined as those who have progressed during or after receiving at least one dose of standard therapy given in a first line setting. a. Disease progression should be confirmed by CT scan. In certain situations, clinical evidence of disease progression such as any new or worsening malignant effusion (documented by ultrasound) and confirmation by pathologic criteria (histology and/or cytology) may be acceptable. b. Treatment with curative intent, including neoadjuvant/adjuvant treatment, given as chemotherapy or chemoradiotherapy, using standard of care agents or definitive chemoradiation, will count as a line of therapy if disease progression occurs during treatment or within 6 months of cessation of treatment. c. Dose reduction and/or switching of one or more first line agents due to toxicity/intolerability as deemed clinically appropriate by the investigator will not constitute a new line of therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "331e59d6-8564-430c-b47c-f423753631ba",
            "name": "Tissue Sample Provision",
            "text": "Provide either a newly obtained or archival tissue sample for intratumoral immune-related GEP analysis and PD-L1 by immunohistochemistry analysis. Newly-obtained tissue is preferred. Formalin-fixed, paraffin-embedded (FFPE) block specimens are preferred to slides. Repeat samples will be required if none of the samples submitted (archived or newly obtained) is adequate. For purposes of this study, newly-obtained tissue refers to tissue that was collected between the last line of therapy and the first dose of study medication. a. Central laboratory confirmation of tumor tissue sample adequacy is required prior to subject randomization in the study. If multiple tumor samples are submitted, at least one of the samples must be confirmed to be adequate by the central laboratory prior to subject being enrolled. b. Subjects from whom newly-obtained samples cannot be obtained (e.g. inaccessible or subject safety concern) an archived specimen may be submitted. c. If newly obtained tissue is provided and an archived tissue sample is available, it should also be provided to support evaluation of the clinical utility of immune-related GEP assessment and PD-L1 analysis by immunohistochemistry in newly obtained vs. archived tissue samples; however, a subject will not be excluded from participating in the study if he/she has provided newly obtained tissue and an archived tissue sample is not available or is otherwise insufficient for analysis.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1600fe27-e11e-45a1-ba13-e02535c81294",
            "name": "Organ Function",
            "text": "Demonstrate adequate organ function as defined in Table 1 (ANC ≥1,500 /mcL, Platelets ≥100,000 / mcL, Hemoglobin ≥9 g/dL, Creatinine ≤1.5 X ULN or CrCl ≥60 mL/min, Total bilirubin ≤ 1.5 X ULN, AST/ALT ≤ 2.5 X ULN or ≤ 5 X ULN for liver metastases, Albumin ≧2.5 g/dL, INR/PT/aPTT ≤1.5 X ULN).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "06eca800-b75a-4035-90fe-461be0a641c2",
            "name": "Pregnancy Test",
            "text": "Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ad38ce06-a8cc-484f-a36a-f7553779e2e0",
            "name": "Female Contraception",
            "text": "Female subjects of childbearing potential (Section 5.7.2) must be willing to use an adequate method of contraception, as outlined in Section 5.7.2 – Contraception, for the course of the study through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1ea92e67-4207-46b5-968a-872acf05077b",
            "name": "Male Contraception",
            "text": "Male subjects of childbearing potential (Section 5.7.2) must agree to use an adequate method of contraception, as outlined in Section 5.7.2- Contraception, and not to donate sperm starting with the first dose of study therapy through 120 days after the last dose of pembrolizumab or through 180 days after the last dose of paclitaxel, docetaxel, or irinotecan. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0599b36d-c3d0-4ebd-8856-6909f0e4ecb8",
            "name": "Investigational Agent Exclusion",
            "text": "Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment. Note: Subjects who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks since the last dose of the previous investigational agent or device.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "1daebf18-56bd-4aa8-89a4-eff0509f46a7",
            "name": "Autoimmune Disease",
            "text": "Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "d11a0271-772d-4654-a715-8b11fab9e21e",
            "name": "Immunodeficiency/Steroids",
            "text": "Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0e08505b-429e-462a-9ed8-8140e728e69d",
            "name": "CNS Metastases",
            "text": "Has known central nervous system (CNS) metastases and/or carcinomatous meningitis (includes past history or current metastasis).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c5aaea64-0d68-45a9-b265-ff7724be56a6",
            "name": "Recent Anti-cancer Therapy",
            "text": "Has received prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1. The specified 2-week period between last dose of prior therapy and first dose of pembrolizumab is the minimum amount of time required. Subjects may not receive study medication less than 2 weeks from the last dose of a prior therapy. However, a period of more than 2 weeks may be used if indicated both clinically and due to concern between possible negative interactions between prior therapy and study therapy. Subjects must have recovered from adverse events due to a previously administered agent to baseline toxicity grade or to Grade 1 or less prior to enrollment. Note: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "de09bbcc-f98e-48a2-8d0c-49ff3e60f3b9",
            "name": "Prior PD-1/PD-L1 Therapy",
            "text": "Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or if the subject has previously participated in Merck pembrolizumab (MK-3475) clinical trials.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "fc3b5003-8863-46e5-982e-689bb37dffcb",
            "name": "mAb Hypersensitivity",
            "text": "Previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb).",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "3d536b59-2489-4086-a96e-12bd8f71df9c",
            "name": "Multiple Lines of Therapy",
            "text": "Has experienced documented objective radiographic or clinical disease progression during or after receiving more than 1 line of therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "732c6a75-41a1-4de9-be60-5ede44c7f635",
            "name": "Additional Malignancy",
            "text": "Has a known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include curatively treated basal cell and SCC of the skin and/or curatively resected in situ cervical and/or breast cancers and in situ or intramucosal pharyngeal cancer.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "c9c3f8c1-54dc-4a21-b069-2197baa5350b",
            "name": "Live Vaccine",
            "text": "Has received a live vaccine within 30 days of planned start of pembrolizumab. Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines, and are not allowed.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b154f2be-ca3c-45e1-b2de-f020622f1890",
            "name": "Confounding Conditions",
            "text": "Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject’s participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "0d37e70c-a006-4322-a3b7-f4127f663ca0",
            "name": "HIV History",
            "text": "Has a known history of Human Immunodeficiency Virus (HIV) infection. No HIV testing is required unless mandated by local health authority.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "ec067cef-cffe-41e4-9a86-7518e8fc4eaf",
            "name": "Hepatitis History",
            "text": "Has known history of or is positive for hepatitis B (hepatitis B surface antigen reactive) or known active hepatitis C (hepatitis C virus RNA or hepatitis C antibody is detected). No hepatitis testing is required unless mandated by local health authority.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "074d29bf-8288-45ba-a8f9-1868cdf15c46",
            "name": "Pneumonitis History",
            "text": "Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "b2f2998c-9821-4097-97f2-8b1eb3a90f1d",
            "name": "Active Infection",
            "text": "Has an active infection requiring systemic therapy.",
            "instanceType": "EligibilityCriterionItem"
          },
          {
            "id": "cff187a9-4266-4259-af70-5808b8bf673f",
            "name": "Psychiatric/Substance Abuse",
            "text": "Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.",
            "instanceType": "EligibilityCriterionItem"
          }
        ],
        "studyInterventions": [
          {
            "id": "29f9daa4-c7d5-4298-94d6-3ad5387ef007",
            "name": "Pembrolizumab (MK-3475)",
            "type": {
              "id": "d911ba73-a439-4d34-854b-350d524e9054",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "role": {
              "id": "6c34fa1c-fde3-43f2-856c-ef42d81443c9",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Anti-PD-1 monoclonal antibody for advanced/metastatic esophageal cancer",
            "productIds": [
              "dc2659b0-b623-45a0-b76f-cc88b8065f45"
            ],
            "administrationIds": [
              "c7e7468f-b5d4-4cc0-a8d7-d6372c496ab3",
              "9620b309-aac3-4b84-abeb-b399535b9e18",
              "d2720ed8-edd5-4bd8-965a-063450639118"
            ]
          },
          {
            "id": "dbdcd631-b92b-49df-8dd7-2b90decdca67",
            "name": "Paclitaxel",
            "type": {
              "id": "8cd9ac7a-7861-45f4-85f9-484a7f1d2b72",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "ed6042f8-5d56-4ec0-8e0b-823df91e534c",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Physician's choice chemotherapy",
            "productIds": [
              "3cf59eb0-ec28-46a8-8ccf-ab4e6da19b7a"
            ],
            "administrationIds": [
              "870826c9-268d-47de-a334-7c808a461ec8",
              "34e29dd7-5a1f-4ae3-be3c-75b7cc0ad019"
            ]
          },
          {
            "id": "47c6eed1-2b34-46a1-8f71-420daffc5c09",
            "name": "Docetaxel",
            "type": {
              "id": "a9267d3a-5146-42af-afbc-5552afc6a0e7",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "68dcb0e6-2b9d-4ded-961e-ced9a2f7529c",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Physician's choice chemotherapy",
            "productIds": [
              "81861d6a-1a73-484b-94d4-1b277a8d4717"
            ],
            "administrationIds": [
              "961a532e-222f-4dac-88a1-65f38b10ba10",
              "34deb3bc-452d-476f-97a6-0a70dd8e1906"
            ]
          },
          {
            "id": "32fa0f84-ca1e-4073-ae4f-4c26e2c00e8d",
            "name": "Irinotecan",
            "type": {
              "id": "fa51d2a3-cccf-4e39-b5f5-750fa7977e5e",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "role": {
              "id": "def84b10-042f-4d3a-ae1d-17b2c4ea1465",
              "code": "C54129",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Comparator",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Physician's choice chemotherapy",
            "productIds": [
              "a004bacb-5a47-4710-97fc-ef9c4b05227c"
            ],
            "administrationIds": [
              "9aaebe0f-0f3c-478d-94ab-45f1420b0ab2",
              "38864379-b602-4d25-9d28-d6b33fca96fd"
            ]
          },
          {
            "id": "7a9cbfd9-b152-4541-9c66-84786da422e9",
            "name": "Corticosteroids",
            "type": {
              "id": "7126da52-e162-4417-ad9c-ae7c1bab6e17",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "e846297d-c629-4b1a-a885-70a47429b70f",
              "code": "C54125",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Rescue Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Used for management of immune-related adverse events and as premedication for chemotherapy"
          },
          {
            "id": "28656f74-7e3a-4b1c-af45-c5271ba8c660",
            "name": "Antihistamines",
            "type": {
              "id": "7fcfae4f-2cb6-4447-8b7a-c6180421338b",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "7d52087c-1859-487c-b1d3-d84b16cf4873",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Permitted for infusion reaction management and chemotherapy premedication"
          },
          {
            "id": "6012ca5d-3c7e-492a-9809-3e3888290436",
            "name": "Antineoplastic systemic chemotherapy",
            "type": {
              "id": "8486f390-59f6-402e-a9a2-8804ebb04b35",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "50941b70-366d-4c9b-ad51-72b725c5d60f",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited during screening and treatment phase unless specified in protocol"
          },
          {
            "id": "0879ab4f-c022-4d71-bd6b-8c0f7cfed13f",
            "name": "Live vaccines",
            "type": {
              "id": "5b18fa8c-a914-4b77-8a10-22654d06213e",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "role": {
              "id": "cbed3155-84b9-4c0d-b129-ef17ca776c8c",
              "code": "C54126",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Concomitant Medication",
              "instanceType": "Code"
            },
            "instanceType": "StudyIntervention",
            "description": "Prohibited within 30 days prior to first dose and during trial for pembrolizumab arm"
          }
        ],
        "administrableProducts": [
          {
            "id": "dc2659b0-b623-45a0-b76f-cc88b8065f45",
            "name": "Pembrolizumab",
            "administrableDoseForm": {
              "id": "a394eb07-58d3-4151-96b6-63f96c7ac585",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "d5a68ea8-66e3-43f2-9803-d951f98152f2",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "56b7d816-ed94-4a2e-9f29-bba1b807f751",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified in provided text",
            "substanceIds": [
              "e4a84fad-3d18-4a29-891d-8a92f4418eaf"
            ],
            "manufacturer": "Merck Sharp & Dohme Corp."
          },
          {
            "id": "3cf59eb0-ec28-46a8-8ccf-ab4e6da19b7a",
            "name": "Paclitaxel",
            "administrableDoseForm": {
              "id": "e9fa2f06-b394-4d04-9daa-02c7ac53bd25",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "bff8d641-1baf-4a03-b2e6-06aa25cacdfa",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "ab2b69b5-93ca-48f8-af67-227db476ce4e",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified in provided text",
            "substanceIds": [
              "a59afd6c-25a4-42ad-8a78-01f14629ee01"
            ],
            "manufacturer": "Not specified"
          },
          {
            "id": "81861d6a-1a73-484b-94d4-1b277a8d4717",
            "name": "Docetaxel",
            "administrableDoseForm": {
              "id": "f3b4d27e-4d48-47fb-9602-0b3cb04d2fc6",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "c140a68f-add0-4d94-b645-8dcb07d29474",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "05181f94-3aeb-4811-aefa-d64f7ea1a8c8",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified in provided text",
            "substanceIds": [
              "681125d5-4577-4004-b63d-b712d3bce2d8"
            ],
            "manufacturer": "Not specified"
          },
          {
            "id": "a004bacb-5a47-4710-97fc-ef9c4b05227c",
            "name": "Irinotecan",
            "administrableDoseForm": {
              "id": "a7ea2f3f-62a8-4f5c-9066-29515f11e149",
              "code": "C42945",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Injection",
              "instanceType": "Code",
              "standardCode": {
                "id": "d00b34cc-c1ee-4109-9451-57448481aac0",
                "code": "C42945",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Injection",
                "instanceType": "Code"
              }
            },
            "productDesignation": {
              "id": "a70187b4-229f-4059-b713-ccb765e1da06",
              "code": "C54121",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "25.01d",
              "decode": "Investigational Product",
              "instanceType": "Code"
            },
            "instanceType": "AdministrableProduct",
            "strength": "Not specified in provided text",
            "substanceIds": [
              "f070936d-940a-42de-ab7a-56801eaa6f71"
            ],
            "manufacturer": "Not specified"
          }
        ],
        "narrativeContents": [
          {
            "id": "76c031b2-ef5f-4b80-b26a-0c3fa2c5d587",
            "name": "TRIAL SUMMARY",
            "text": "TRIAL SUMMARY",
            "order": 0,
            "instanceType": "NarrativeContent",
            "sectionNumber": "1.0",
            "sectionTitle": "TRIAL SUMMARY",
            "sectionType": {
              "id": "781befe8-5b84-4481-82f7-c344bb6fa8a7",
              "code": "Synopsis",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Synopsis",
              "instanceType": "Code"
            }
          },
          {
            "id": "5aab0f28-5450-4dc8-845f-22faa3e0a2a5",
            "name": "TRIAL DESIGN",
            "text": "TRIAL DESIGN",
            "order": 1,
            "instanceType": "NarrativeContent",
            "sectionNumber": "2.0",
            "sectionTitle": "TRIAL DESIGN",
            "sectionType": {
              "id": "f867a1b2-51ae-4aca-89eb-2f108256910a",
              "code": "Study Design",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Study Design",
              "instanceType": "Code"
            },
            "childIds": [
              "6bec25e6-72ff-4b3e-93bc-391bef530bee",
              "56763a8f-b294-4a44-b61d-e6e378637793"
            ]
          },
          {
            "id": "8e4d94e7-6bb4-4432-a394-19bddf99d4ce",
            "name": "OBJECTIVE(S) & HYPOTHESIS(ES)",
            "text": "OBJECTIVE(S) & HYPOTHESIS(ES)",
            "order": 2,
            "instanceType": "NarrativeContent",
            "sectionNumber": "3.0",
            "sectionTitle": "OBJECTIVE(S) & HYPOTHESIS(ES)",
            "sectionType": {
              "id": "b9c98d12-828c-42c4-820b-4fd993b0f05d",
              "code": "Objectives",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Objectives",
              "instanceType": "Code"
            },
            "childIds": [
              "01d72438-7be4-4daf-a45b-00bf4edd5481",
              "d53c9c53-6263-4539-91d5-0a6cbae812c8",
              "cd4b0afb-bc2f-4096-955d-6c1da85dffa0"
            ]
          },
          {
            "id": "82888636-e873-44f5-b5fd-0bf44a733f73",
            "name": "BACKGROUND & RATIONALE",
            "text": "BACKGROUND & RATIONALE",
            "order": 3,
            "instanceType": "NarrativeContent",
            "sectionNumber": "4.0",
            "sectionTitle": "BACKGROUND & RATIONALE",
            "sectionType": {
              "id": "1f0b515f-2524-4116-aa45-1a01ca0c44c2",
              "code": "Introduction",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Introduction",
              "instanceType": "Code"
            },
            "childIds": [
              "352b5b81-fa38-40c0-8e55-9cd24338fe18",
              "1c3e8b69-85fb-4258-b40a-6ba70637abaa",
              "e966bd58-2f95-476e-86d9-28b845321567",
              "fa708d5d-5c86-4b61-a6f7-f0288a5607fc",
              "082b447d-a310-4008-8c65-037c08429890",
              "1e367422-4259-4e85-9c2f-d9a4311928fb",
              "ad6a6ad2-3967-432c-a1c7-589acf06d15f"
            ]
          },
          {
            "id": "06b02b42-1bc2-4c87-a73c-7330429205e6",
            "name": "LIST OF REFERENCES",
            "text": "LIST OF REFERENCES",
            "order": 4,
            "instanceType": "NarrativeContent",
            "sectionNumber": "11.0",
            "sectionTitle": "LIST OF REFERENCES",
            "sectionType": {
              "id": "0af17d01-8345-4f0b-aeb6-7b6687bb7395",
              "code": "References",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "References",
              "instanceType": "Code"
            }
          },
          {
            "id": "74efd3c1-447c-426a-99a8-d2ea0a518bf0",
            "name": "APPENDICES",
            "text": "APPENDICES",
            "order": 5,
            "instanceType": "NarrativeContent",
            "sectionNumber": "12.0",
            "sectionTitle": "APPENDICES",
            "sectionType": {
              "id": "989838b5-2ece-4cbc-be60-827483a36c6b",
              "code": "Appendix",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Appendix",
              "instanceType": "Code"
            },
            "childIds": [
              "e75141cc-1282-43b6-a023-1d86887addcc",
              "7f501601-4066-4466-993e-4a7b198417d0",
              "dd501d8d-37f1-413b-b930-2dae491d7f7e",
              "9b592fe6-6c08-43a5-b73d-09f3f96c784b",
              "9774ed97-d4f8-427b-9f16-744566677616",
              "985e09c1-927a-4e4f-a408-41ae145cf13c"
            ]
          },
          {
            "id": "384a1e5d-a147-4420-a3ed-f7719ac2eb63",
            "name": "SIGNATURES",
            "text": "SIGNATURES",
            "order": 6,
            "instanceType": "NarrativeContent",
            "sectionNumber": "13.0",
            "sectionTitle": "SIGNATURES",
            "sectionType": {
              "id": "7b4e6ecb-02e8-4a4d-bc06-3c281ab28c2c",
              "code": "Other",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Other",
              "instanceType": "Code"
            }
          }
        ],
        "narrativeContentItems": [
          {
            "id": "6bec25e6-72ff-4b3e-93bc-391bef530bee",
            "name": "Trial Design",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.1",
            "sectionTitle": "Trial Design"
          },
          {
            "id": "56763a8f-b294-4a44-b61d-e6e378637793",
            "name": "Trial Diagram",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "2.2",
            "sectionTitle": "Trial Diagram"
          },
          {
            "id": "01d72438-7be4-4daf-a45b-00bf4edd5481",
            "name": "Primary Objective(s) & Hypothesis(es)",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.1",
            "sectionTitle": "Primary Objective(s) & Hypothesis(es)"
          },
          {
            "id": "d53c9c53-6263-4539-91d5-0a6cbae812c8",
            "name": "Secondary Objective(s) & Hypothesis(es)",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.2",
            "sectionTitle": "Secondary Objective(s) & Hypothesis(es)"
          },
          {
            "id": "cd4b0afb-bc2f-4096-955d-6c1da85dffa0",
            "name": "Exploratory Objectives",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "3.3",
            "sectionTitle": "Exploratory Objectives"
          },
          {
            "id": "352b5b81-fa38-40c0-8e55-9cd24338fe18",
            "name": "Background",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1",
            "sectionTitle": "Background"
          },
          {
            "id": "1c3e8b69-85fb-4258-b40a-6ba70637abaa",
            "name": "Pharmaceutical and Therapeutic Background",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1.1",
            "sectionTitle": "Pharmaceutical and Therapeutic Background"
          },
          {
            "id": "e966bd58-2f95-476e-86d9-28b845321567",
            "name": "Pre-clinical and Clinical Trials",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.1.2",
            "sectionTitle": "Pre-clinical and Clinical Trials"
          },
          {
            "id": "fa708d5d-5c86-4b61-a6f7-f0288a5607fc",
            "name": "Rationale",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2",
            "sectionTitle": "Rationale"
          },
          {
            "id": "082b447d-a310-4008-8c65-037c08429890",
            "name": "Rationale for the Trial and Selected Subject Population",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2.1",
            "sectionTitle": "Rationale for the Trial and Selected Subject Population"
          },
          {
            "id": "1e367422-4259-4e85-9c2f-d9a4311928fb",
            "name": "Rationale for Dose Selection/Regimen/Modification",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2.2",
            "sectionTitle": "Rationale for Dose Selection/Regimen/Modification"
          },
          {
            "id": "ad6a6ad2-3967-432c-a1c7-589acf06d15f",
            "name": "Rationale for Endpoints",
            "text": "",
            "order": 6,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "4.2.3",
            "sectionTitle": "Rationale for Endpoints"
          },
          {
            "id": "e75141cc-1282-43b6-a023-1d86887addcc",
            "name": "Merck Code of Conduct for Clinical Trials",
            "text": "",
            "order": 0,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.1",
            "sectionTitle": "Merck Code of Conduct for Clinical Trials"
          },
          {
            "id": "7f501601-4066-4466-993e-4a7b198417d0",
            "name": "Collection and Management of Specimens for Future Biomedical Research",
            "text": "",
            "order": 1,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.2",
            "sectionTitle": "Collection and Management of Specimens for Future Biomedical Research"
          },
          {
            "id": "dd501d8d-37f1-413b-b930-2dae491d7f7e",
            "name": "Response Evaluation Criteria in Solid Tumors",
            "text": "",
            "order": 2,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.4",
            "sectionTitle": "Response Evaluation Criteria in Solid Tumors"
          },
          {
            "id": "9b592fe6-6c08-43a5-b73d-09f3f96c784b",
            "name": "ECOG Performance Status",
            "text": "",
            "order": 3,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.5",
            "sectionTitle": "ECOG Performance Status"
          },
          {
            "id": "9774ed97-d4f8-427b-9f16-744566677616",
            "name": "Common Terminology Criteria for Adverse Events",
            "text": "",
            "order": 4,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.6",
            "sectionTitle": "Common Terminology Criteria for Adverse Events"
          },
          {
            "id": "985e09c1-927a-4e4f-a408-41ae145cf13c",
            "name": "List of Abbreviations",
            "text": "",
            "order": 5,
            "instanceType": "NarrativeContentItem",
            "sectionNumber": "12.7",
            "sectionTitle": "List of Abbreviations"
          }
        ],
        "abbreviations": [
          {
            "id": "168e0743-a1b8-41c4-99d4-32bb9bd4f006",
            "abbreviatedText": "GEP",
            "expandedText": "Gene Expression Profile",
            "instanceType": "Abbreviation"
          },
          {
            "id": "764075c3-8e28-4d5c-9354-091866ca2629",
            "abbreviatedText": "irRECIST",
            "expandedText": "Immune-related RECIST",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7c81e823-4f18-4d63-83ab-e5451aa947b8",
            "abbreviatedText": "IRBs",
            "expandedText": "Institutional Review Boards",
            "instanceType": "Abbreviation"
          },
          {
            "id": "d0c43c7c-41aa-4753-9373-1af2f77f1c19",
            "abbreviatedText": "IECs",
            "expandedText": "Independent Ethics Committees",
            "instanceType": "Abbreviation"
          },
          {
            "id": "7204e936-6420-4ab4-bee8-08f56be519f9",
            "abbreviatedText": "ECOG",
            "expandedText": "Eastern Cooperative Oncology Group",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5882cb0d-22e2-4a56-bab3-8b45269b907f",
            "abbreviatedText": "AE",
            "expandedText": "adverse event",
            "instanceType": "Abbreviation"
          },
          {
            "id": "ca270fb4-4793-40f4-bd3f-0a37797db68f",
            "abbreviatedText": "SAE",
            "expandedText": "Serious adverse events",
            "instanceType": "Abbreviation"
          },
          {
            "id": "5a905617-88b6-4a86-8cae-60195dd86feb",
            "abbreviatedText": "CR",
            "expandedText": "complete response",
            "instanceType": "Abbreviation"
          },
          {
            "id": "278bbae3-d910-4128-928e-05308b470ebd",
            "abbreviatedText": "EGJ",
            "expandedText": "esophagogastric junction",
            "instanceType": "Abbreviation"
          },
          {
            "id": "054dd649-fd8c-4f44-8370-b3713547c988",
            "abbreviatedText": "PD-L1",
            "expandedText": "Programmed Death-Ligand 1",
            "instanceType": "Abbreviation"
          }
        ],
        "amendments": [
          {
            "id": "6704d1f7-8625-4ffe-ac24-014225e05714",
            "number": "06",
            "name": "Amendment 06",
            "scope": {
              "id": "6a632bbc-ae84-45c5-88ed-4ea94eb089f1",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "32a2e1fe-54b7-4f1d-ae77-2d7b2edcc7b6",
              "code": {
                "id": "4497a599-2ca5-472e-b018-8f430778b551",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "300a3863-3d00-44e0-8bd7-823a21132241",
                "type": {
                  "id": "9417ae43-dfae-4b42-bcac-f5ebe736c331",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "To update the dose modification and toxicity management guidelines for irAEs and to clarify the concomitant use of COVID-19 vaccines. The update to irAE guidelines was requested by the FDA to harmonize safety information across PD-1/L1 antibody prescribing information.",
            "effectiveDate": "2021-06-25",
            "reasonIds": [
              "a187deef-2f51-41e8-bb1f-8be233abe78f",
              "5ad2cd55-743d-4a6c-a840-2a6dfe7b0301",
              "5f805498-4e1d-430e-8603-30d4e1967553"
            ],
            "previousVersion": "05",
            "newVersion": "06"
          },
          {
            "id": "98feccf4-b260-4ebe-9fa2-9d86293502cf",
            "number": "05",
            "name": "Amendment 05",
            "scope": {
              "id": "84f0630b-245e-477a-a3da-9e5843ee31b1",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "e86d5988-e131-4167-9c75-7d7e4ad5ce82",
              "code": {
                "id": "578dd45a-fb48-40a2-9bdf-be386a2bb818",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "51c0242b-e657-4799-8770-8876ea6d040a",
                "type": {
                  "id": "fc1340f8-09de-4ba5-9730-553c37f48d36",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The alpha spending function to control the Type-I error based on information fraction was replaced with one based on specified calendar time fraction (0.76). Due to potential delayed treatment effects that have been observed with immunotherapy, the stratified log-rank test was replaced by a stratified max-combo test for testing the OS and PFS hypotheses in all subjects.",
            "effectiveDate": "2018-03-08",
            "reasonIds": [
              "563df74b-2188-49dd-acba-964bec3ade1e",
              "ab97c4bd-7aba-4160-9363-ab38e1386c2c"
            ],
            "previousVersion": "04",
            "newVersion": "05"
          },
          {
            "id": "7b1216bf-0164-4c3c-9f50-9b1886df2cd6",
            "number": "04",
            "name": "Amendment 04",
            "scope": {
              "id": "d17f5a6e-7c66-4cb7-87df-575749da305e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "c0d9a187-2c8d-4fc8-a59f-10316cb660fc",
              "code": {
                "id": "6e12638f-7a16-416a-8484-f7d84fb6118a",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "0b20f67e-dd2f-463e-b409-34f13a8930f8",
                "type": {
                  "id": "109693c7-0250-4480-9d38-f8f25cc5bf7e",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "The primary objectives were changed from dual endpoints of OS and PFS to a single endpoint of OS, based on recommendations from emerging data in MK-3475-KEYNOTE-180. The timing of the interim and final analyses was updated in order to wait for more mature OS data and account for a potential delayed separation in survival curves observed in immuno-oncology studies.",
            "effectiveDate": "2017-08-03",
            "reasonIds": [
              "0f03c4ca-654b-4ab2-9e85-17fa04f5963f",
              "054177b0-a255-4390-bffd-5bb7ff395a5c"
            ],
            "previousVersion": "03",
            "newVersion": "04"
          },
          {
            "id": "c2656abb-e6cf-43d5-8645-b0d8c52a20ab",
            "number": "03",
            "name": "Amendment 03",
            "scope": {
              "id": "b7468d18-3b86-4dc1-be77-044e38c96ecd",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "e71c6c3e-9663-44f7-a31e-6e0610e9a4bc",
              "code": {
                "id": "c64e8e11-7dca-4526-a74b-7d419a6da402",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "dbd8fb87-1304-44d6-89b0-01660f7d8a6e",
                "type": {
                  "id": "d039d635-2d0f-4136-8fa1-faaffc7c630b",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "To extend the enrollment period beyond the Global Cohort to achieve the required sample size of the China Cohort and the number of events to investigate efficacy and safety in Chinese 2L EC subjects.",
            "effectiveDate": "2017-03-29",
            "reasonIds": [
              "b3235b53-ae22-425f-bff7-d7efa68b5ec9",
              "03ed77e1-f21b-4c3d-ac92-f765128c2c0b"
            ],
            "previousVersion": "02",
            "newVersion": "03"
          },
          {
            "id": "fb5bcee0-6208-43cf-8b60-bf1cd66ca28f",
            "number": "02",
            "name": "Amendment 02",
            "scope": {
              "id": "38318d8f-47f7-4571-88e1-02fdf8ac9822",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "primaryReason": {
              "id": "762df0fc-07bb-4560-a39c-74a5847dffa7",
              "code": {
                "id": "93a6e882-498f-48ed-9f6d-5b4293838fc7",
                "code": "C98782",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "25.01d",
                "decode": "Protocol Amendment",
                "instanceType": "Code"
              },
              "otherReason": "Protocol Amendment",
              "instanceType": "StudyAmendmentReason"
            },
            "geographicScopes": [
              {
                "id": "83644631-ee6a-4c9f-8c29-33d16888dae1",
                "type": {
                  "id": "5efd2260-3aac-4c2b-a10a-4860b1b01f63",
                  "code": "Global",
                  "codeSystem": "USDM",
                  "codeSystemVersion": "2024-09-27",
                  "decode": "Global",
                  "instanceType": "Code"
                },
                "instanceType": "GeographicScope"
              }
            ],
            "instanceType": "StudyAmendment",
            "summary": "Sections were revised to identify GEP low, intermediate, and high tumors; to describe the development of GEP cut-off 'GEP intermediate or high' and/or to describe how the primary, secondary, and exploratory objectives and endpoints will be met and analyzed.",
            "effectiveDate": "2016-12-09",
            "reasonIds": [
              "623b58c0-cd57-4c82-bbfd-307ef14c605f",
              "d20804d3-b65d-410f-a17b-ac365c1499cf"
            ],
            "previousVersion": "01",
            "newVersion": "02"
          }
        ],
        "medicalDevices": [
          {
            "id": "da9ec9db-db8b-4b07-9d2f-359ff81bc450",
            "name": "Infusion Pump",
            "instanceType": "MedicalDevice",
            "label": "Infusion Pump",
            "description": "Device used to control the rate of intravenous drug administration",
            "deviceType": {
              "id": "3b55dc91-0431-447b-bab4-5a01e9878b1c",
              "code": "Drug Delivery Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Drug Delivery Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "9a86cdfa-a511-442f-ab1c-8af3ddd8aeeb",
            "name": "CT Scanner",
            "instanceType": "MedicalDevice",
            "label": "CT Scanner",
            "description": "Imaging equipment for computed tomography",
            "deviceType": {
              "id": "002fb68c-06c8-424a-a0f9-9ec59d1897e3",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "f40cfc61-5369-45eb-971c-61d829d4e476",
            "name": "MRI Scanner",
            "instanceType": "MedicalDevice",
            "label": "MRI Scanner",
            "description": "Imaging equipment for magnetic resonance imaging",
            "deviceType": {
              "id": "03c39a80-8f9b-4066-93c7-da3e2efc9970",
              "code": "Diagnostic Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Diagnostic Device",
              "instanceType": "Code"
            }
          },
          {
            "id": "bc76b4bc-2c23-4d80-8552-ae269bc3ccd8",
            "name": "ECG Machine",
            "instanceType": "MedicalDevice",
            "label": "ECG Device",
            "description": "Device for recording 12-lead electrocardiograms",
            "deviceType": {
              "id": "9f4db235-eb7b-412e-87ac-c986fd33aa51",
              "code": "Monitoring Device",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Monitoring Device",
              "instanceType": "Code"
            }
          }
        ],
        "conditions": [
          {
            "id": "d791fe62-60ae-4a42-a97c-09ee1df1add4",
            "name": "Complete Response Criteria",
            "instanceType": "Condition",
            "description": "Criteria for stopping therapy early due to CR",
            "text": "Attainment of confirmed CR, received at least 8 cycles total, and at least 2 cycles beyond initial CR declaration."
          },
          {
            "id": "94dee686-b65d-4e8a-ad45-6d240597be88",
            "name": "Retreatment Eligibility",
            "instanceType": "Condition",
            "description": "Criteria for entering Second Course Phase",
            "text": "Radiographic disease progression after stopping for CR or 2 years of treatment, no interim cancer therapy, and meets safety parameters."
          },
          {
            "id": "938d30c2-5d27-4dbf-9f43-2e8dd17ea78a",
            "name": "Infusion Reaction Grade 2",
            "instanceType": "Condition",
            "description": "Criteria for restarting infusion",
            "text": "Symptoms resolve within 1 hour of stopping; restart at 50% original rate."
          }
        ],
        "administrations": [
          {
            "id": "34deb3bc-452d-476f-97a6-0a70dd8e1906",
            "name": "Administration of Docetaxel",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "fb8216b9-2249-48bb-b19d-cd4557a70f02",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "38864379-b602-4d25-9d28-d6b33fca96fd",
            "name": "Administration of Irinotecan",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.ONCE_DAILY",
            "instanceType": "Administration",
            "route": {
              "id": "c0317277-626a-4a2c-adfd-d056c33aa8d0",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "9620b309-aac3-4b84-abeb-b399535b9e18",
            "name": "Administration of Pembrolizumab",
            "description": "RouteOfAdministration.ORAL DosingFrequency.EVERY_THREE_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "86f44aea-23ca-4765-8f11-065ed1ad47a6",
              "code": "C38288",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Oral",
              "instanceType": "Code"
            }
          },
          {
            "id": "d2720ed8-edd5-4bd8-965a-063450639118",
            "name": "Administration of Pembrolizumab (MK-3475)",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.EVERY_THREE_WEEKS",
            "instanceType": "Administration",
            "route": {
              "id": "8600e0c6-431f-475d-8d58-96ad5eb440e1",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          },
          {
            "id": "34e29dd7-5a1f-4ae3-be3c-75b7cc0ad019",
            "name": "Administration of Paclitaxel",
            "description": "RouteOfAdministration.INTRAVENOUS DosingFrequency.WEEKLY",
            "instanceType": "Administration",
            "route": {
              "id": "33ac5e9e-7917-4e65-8095-112ffbfcda31",
              "code": "C38276",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "2024-09-27",
              "decode": "Intravenous",
              "instanceType": "Code"
            }
          }
        ],
        "rationale": "Protocol version"
      }
    ],
    "name": "A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs. Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)"
  },
  "administrations": [
    {
      "id": "c7e7468f-b5d4-4cc0-a8d7-d6372c496ab3",
      "name": "Pembrolizumab Regimen",
      "instanceType": "Administration",
      "dose": "200 mg",
      "doseFrequency": "Every 3 weeks",
      "route": {
        "id": "d1a43fd7-b6ea-4287-9fd0-34bae3b458bc",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression, unacceptable toxicity, or 35 administrations (approx. 2 years)"
    },
    {
      "id": "870826c9-268d-47de-a334-7c808a461ec8",
      "name": "Paclitaxel Regimen",
      "instanceType": "Administration",
      "dose": "80-100 mg/m2",
      "doseFrequency": "Days 1, 8, and 15 of every 28-day cycle",
      "route": {
        "id": "70d1c54f-d7c2-488c-bb0f-2df6a9292cce",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression or unacceptable toxicity"
    },
    {
      "id": "961a532e-222f-4dac-88a1-65f38b10ba10",
      "name": "Docetaxel Regimen",
      "instanceType": "Administration",
      "dose": "75 mg/m2",
      "doseFrequency": "Day 1 of every 21-day cycle",
      "route": {
        "id": "95a313b8-b796-486e-a65e-7ba6e45713e7",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression or unacceptable toxicity"
    },
    {
      "id": "9aaebe0f-0f3c-478d-94ab-45f1420b0ab2",
      "name": "Irinotecan Regimen",
      "instanceType": "Administration",
      "dose": "180 mg/m2",
      "doseFrequency": "Day 1 of every 14-day cycle",
      "route": {
        "id": "e5f418dd-8a20-4510-a6bc-e3b30794edf5",
        "code": "Intravenous",
        "codeSystem": "USDM",
        "codeSystemVersion": "2024-09-27",
        "decode": "Intravenous",
        "instanceType": "Code"
      },
      "duration": "Until disease progression or unacceptable toxicity"
    }
  ],
  "substances": [
    {
      "id": "e4a84fad-3d18-4a29-891d-8a92f4418eaf",
      "name": "Pembrolizumab",
      "instanceType": "Substance",
      "description": "Humanized monoclonal antibody against PD-1"
    },
    {
      "id": "a59afd6c-25a4-42ad-8a78-01f14629ee01",
      "name": "Paclitaxel",
      "instanceType": "Substance",
      "description": "Taxane antineoplastic agent"
    },
    {
      "id": "681125d5-4577-4004-b63d-b712d3bce2d8",
      "name": "Docetaxel",
      "instanceType": "Substance",
      "description": "Taxane antineoplastic agent"
    },
    {
      "id": "f070936d-940a-42de-ab7a-56801eaa6f71",
      "name": "Irinotecan",
      "instanceType": "Substance",
      "description": "Topoisomerase I inhibitor"
    }
  ],
  "studyDefinitionDocument": {
    "id": "f3736169-dc29-4947-8c85-9e312dae45e4",
    "name": "MK-3475-181-06 Final Protocol: A randomized, multi-center, open-label trial of pembrolizumab (MK-3475) versus the investigator’s choice of paclitaxel, docetaxel, or irinotecan in subjects with advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus, or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ)",
    "documentType": "Protocol",
    "language": "en",
    "instanceType": "StudyDefinitionDocument",
    "version": "181-06",
    "versionDate": "25-Jun-2021",
    "contentIds": [
      "76c031b2-ef5f-4b80-b26a-0c3fa2c5d587",
      "5aab0f28-5450-4dc8-845f-22faa3e0a2a5",
      "8e4d94e7-6bb4-4432-a394-19bddf99d4ce",
      "82888636-e873-44f5-b5fd-0bf44a733f73",
      "06b02b42-1bc2-4c87-a73c-7330429205e6",
      "74efd3c1-447c-426a-99a8-d2ea0a518bf0",
      "384a1e5d-a147-4420-a3ed-f7719ac2eb63"
    ]
  },
  "geographicScope": {
    "id": "dd7d683a-de33-4b5b-8f85-f2ecc2d36dad",
    "name": "Study Geographic Scope",
    "scopeType": "Global",
    "instanceType": "GeographicScope",
    "countryIds": [
      "3cc565f2-c7bd-46fc-a607-7c942376ebb8",
      "249930f0-401b-4304-813b-7bb2c5ed2ca8"
    ],
    "regions": [
      "Global",
      "China"
    ]
  },
  "countries": [
    {
      "id": "3cc565f2-c7bd-46fc-a607-7c942376ebb8",
      "name": "China",
      "instanceType": "Country",
      "code": "CN"
    },
    {
      "id": "249930f0-401b-4304-813b-7bb2c5ed2ca8",
      "name": "United States",
      "instanceType": "Country",
      "code": "US"
    }
  ],
  "ingredients": [
    {
      "id": "7a3df50a-8f39-4116-9160-c045b0117354",
      "name": "Pembrolizumab",
      "role": "Active",
      "instanceType": "Ingredient",
      "substanceId": "536ce36a-704f-45f3-8d09-cd0da4be9243"
    },
    {
      "id": "81e9762d-7ac0-4c2f-9a53-25777aa4419c",
      "name": "Paclitaxel",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "ddb839a4-c689-4482-b587-fd80b994dfb9",
      "name": "Docetaxel",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "37fbb837-0cf0-43b5-9a49-4d768467ae09",
      "name": "Irinotecan",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "0f83d16c-a4af-42c3-82b4-e2ab0124a624",
      "name": "Dexamethasone",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "fed83ed4-2b7f-43b1-862a-cdafa2ab8ff2",
      "name": "Diphenhydramine hydrochloride",
      "role": "Active",
      "instanceType": "Ingredient"
    },
    {
      "id": "a30880f8-5e65-498c-a78a-8246e6bfb13a",
      "name": "Ondansetron",
      "role": "Active",
      "instanceType": "Ingredient"
    }
  ],
  "strengths": [
    {
      "id": "ee9427bb-b601-4b20-af71-ff83dff60672",
      "instanceType": "Strength",
      "value": 200,
      "unit": "mg",
      "numerator": {
        "value": 200,
        "unit": "mg"
      }
    },
    {
      "id": "035a1bfb-21c6-45f6-b626-98fe9a7f46d8",
      "instanceType": "Strength",
      "value": 80,
      "unit": "mg/m2",
      "numerator": {
        "value": 80,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "m2"
      }
    },
    {
      "id": "5273b1ca-603b-4ce7-bf3f-2c9f9b721ca7",
      "instanceType": "Strength",
      "value": 100,
      "unit": "mg/m2",
      "numerator": {
        "value": 100,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "m2"
      }
    },
    {
      "id": "90daa96f-c61f-434c-afab-59e01ff53f8f",
      "instanceType": "Strength",
      "value": 75,
      "unit": "mg/m2",
      "numerator": {
        "value": 75,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "m2"
      }
    },
    {
      "id": "6fb9c421-6206-4b7c-8956-74fdd85cfac7",
      "instanceType": "Strength",
      "value": 180,
      "unit": "mg/m2",
      "numerator": {
        "value": 180,
        "unit": "mg"
      },
      "denominator": {
        "value": 1,
        "unit": "m2"
      }
    }
  ],
  "transitionRules": [
    {
      "id": "78e68390-601c-4eac-846c-f0249e33963e",
      "name": "Transition to Second Course",
      "instanceType": "TransitionRule",
      "transitionType": "Epoch Transition",
      "fromElementId": "Initial Treatment",
      "toElementId": "Second Course Phase",
      "text": "Subjects who progress after 35 administrations or after stopping for CR may receive up to 1 year of retreatment."
    },
    {
      "id": "5f9049e9-c5dd-4fb7-98e9-44c11c515d57",
      "name": "Dose Modification for irAE",
      "instanceType": "TransitionRule",
      "transitionType": "Dose Modification",
      "text": "Withhold or permanently discontinue pembrolizumab based on severity of immune-related AEs per Table 3."
    },
    {
      "id": "31b5bf37-b61d-4fbb-a368-0dd6f85023d5",
      "name": "Safety Discontinuation",
      "instanceType": "TransitionRule",
      "transitionType": "Discontinuation",
      "text": "Discontinue for recurrent Grade 2 pneumonitis or confirmed positive pregnancy test."
    }
  ],
  "documentContentReferences": [
    {
      "id": "68a438b4-8e0d-4101-92ad-c518a9b1fcf2",
      "name": "Trial Flow Chart Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "6.0",
      "sectionTitle": "TRIAL FLOW CHART",
      "description": "Reference for specific procedures and visit windows"
    },
    {
      "id": "0bc8efef-73cd-4323-a969-c169014adfd9",
      "name": "Trial Procedures Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.0",
      "sectionTitle": "TRIAL PROCEDURES",
      "description": "Reference for details of each procedure"
    },
    {
      "id": "3867e73f-0d1b-4788-b09e-35809572a8fe",
      "name": "Stratification Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.4",
      "sectionTitle": "Stratification",
      "description": "Reference to stratification factors for randomization"
    },
    {
      "id": "c914f8af-bd32-43dc-9356-347d0d47ef78",
      "name": "irRECIST Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.1.4.1.5",
      "sectionTitle": "immune-related RECIST (irRECIST)",
      "description": "Reference for the adaptation of RECIST 1.1"
    },
    {
      "id": "73f033d8-2e48-4fc3-9949-33a85ddaa10d",
      "name": "Interim Analysis Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "8.7",
      "sectionTitle": "Statistical Analysis Plan",
      "description": "Reference for details on formal interim efficacy analysis"
    },
    {
      "id": "83e6a48b-9226-45ee-ae60-943ae7d936eb",
      "name": "Abbreviations Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "12.7",
      "sectionTitle": "Abbreviations",
      "description": "Reference for the list of abbreviations used in the document"
    },
    {
      "id": "456edc86-1c00-4dde-81b9-63ca6ce291e5",
      "name": "CTCAE Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "12.6",
      "sectionTitle": "NCI Common Terminology Criteria for Adverse Events",
      "description": "Reference for toxicity definitions and grading"
    },
    {
      "id": "752151d6-dbf4-436b-a55f-f1e57b7ec289",
      "name": "Dose Modification Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "5.2.1",
      "sectionTitle": "Dose Selection/Modification",
      "description": "Reference for dose modification guidelines"
    },
    {
      "id": "13782026-e43f-4d4d-9462-03075b9f7992",
      "name": "Unblinding Reference",
      "instanceType": "DocumentContentReference",
      "sectionNumber": "7.1.5.2",
      "sectionTitle": "Blinding/Unblinding",
      "description": "Reference for method of unblinding a subject"
    }
  ],
  "commentAnnotations": [
    {
      "id": "6df7d074-b4e2-45bc-a0f7-ad9024312ef2",
      "text": "In cases of anaphylaxis, epinephrine should be used immediately.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Table 4: Pembrolizumab Infusion Reaction Dose modification and Treatment Guidelines",
      "pageNumber": 45
    },
    {
      "id": "e227b673-2b1c-4779-a804-939f9daaba26",
      "text": "Any COVID-19 vaccine that is licensed in a given country is allowed in the study.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "5.5.2 Prohibited Concomitant Medication",
      "pageNumber": 14
    },
    {
      "id": "ef20f763-2305-450a-a432-f7aa97dc415e",
      "text": "If after the evaluation the event is determined not to be related to pembrolizumab, the investigator does not need to follow the treatment guidance.",
      "annotationType": "Note",
      "instanceType": "CommentAnnotation",
      "sourceSection": "Supportive Care Guidelines for Pembrolizumab",
      "pageNumber": 50
    },
    {
      "id": "e32c0089-c5e7-4f37-8630-1d43736571bf",
      "text": "Siewert type I tumors are adenocarcinomas of the lower esophagus with the center located within 1cm to 5cm above the anatomic EGJ.",
      "annotationType": "Clarification",
      "instanceType": "CommentAnnotation",
      "sourceSection": "2.0 TRIAL DESIGN",
      "pageNumber": 17
    }
  ],
  "studyDefinitionDocumentVersions": [
    {
      "id": "f89f524d-41e5-4e63-80d2-17e045bcc277",
      "versionNumber": "181-06",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2021-06-25",
      "description": "Update dose modification and toxicity management guidelines for irAEs and clarify COVID-19 vaccine use.",
      "amendmentNumber": "Amendment 6"
    },
    {
      "id": "ab891f99-e088-4f1f-a6bd-2123f1d59e2f",
      "versionNumber": "181-05",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2018-03-08",
      "description": "Alpha spending function replacement and stratified max-combo test implementation.",
      "amendmentNumber": "Amendment 5"
    },
    {
      "id": "a441367a-2e55-47f0-8e44-87c002f222cf",
      "versionNumber": "181-04",
      "status": "Final",
      "instanceType": "StudyDefinitionDocumentVersion",
      "versionDate": "2017-08-03",
      "description": "Primary objectives changed from dual endpoints (OS/PFS) to single endpoint (OS).",
      "amendmentNumber": "Amendment 4"
    }
  ],
  "studyAmendmentImpacts": [
    {
      "id": "e012d875-465f-41eb-89ac-4271572f10ab",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "affectedSection": "Section 5.2.1.2.1 - Immune-Related Events and Dose Modification",
      "impactLevel": "Major",
      "instanceType": "StudyAmendmentImpact",
      "description": "Updated dose modification and toxicity management guidelines for immune-related adverse events (irAEs) and associated tables."
    },
    {
      "id": "c29c6e0a-501d-4bc1-a6c2-50df84363529",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "affectedSection": "Section 5.5.2 - Prohibited Concomitant Medication",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Clarified the status of COVID-19 vaccines as allowed concomitant medication."
    },
    {
      "id": "58fd20dd-a722-4674-adac-031de3ad30c9",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "affectedSection": "Section 5.11 - Clinical Criteria for Early Trial Termination",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Updated criteria to allow for earlier study termination flexibility."
    },
    {
      "id": "b50d4022-ceaa-4c39-bbc9-0ad51cca7055",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "affectedSection": "Section 5.10 - Beginning and End of the Trial",
      "impactLevel": "Minor",
      "instanceType": "StudyAmendmentImpact",
      "description": "Added provisions for subject enrollment into a pembrolizumab extension study."
    }
  ],
  "studyAmendmentReasons": [
    {
      "id": "9daf9438-c148-4fe7-a1a6-3b5ccfff8088",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "reasonText": "Requested by the U.S. Food and Drug Administration (FDA) to harmonize safety information across all FDA-approved PD-1/L1 antibody prescribing information.",
      "category": "Regulatory",
      "isPrimary": true,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "04392218-c295-4caf-8a23-83703643fdf0",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "reasonText": "To clarify the concomitant use of COVID-19 vaccines.",
      "category": "Operational",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "95657b17-9c98-42a2-b7d2-1ac1fbf940ce",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "reasonText": "To add flexibility to allow the study to terminate before the planned completion date.",
      "category": "Administrative",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    },
    {
      "id": "8898a1bd-6a3a-4ef6-a6c4-fb29631f6d99",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "reasonText": "To align text with legal requirements to obtain informed consent documentation.",
      "category": "Regulatory",
      "isPrimary": false,
      "instanceType": "StudyAmendmentReason"
    }
  ],
  "studyChanges": [
    {
      "id": "acb3a9c7-fc02-4fe2-b66c-58e181bbf4ea",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "5.2.1.2.1",
      "beforeText": "Not specified",
      "afterText": "Updated dose modification and toxicity management guidelines for irAEs and table.",
      "summary": "Harmonized irAE management tables with FDA-approved prescribing information for PD-1/L1 antibodies."
    },
    {
      "id": "8f425552-46a3-439e-b717-3ff4cf232d90",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "5.5.2",
      "beforeText": "Not specified",
      "afterText": "Any COVID-19 vaccine that is licensed in a given country is allowed in the study.",
      "summary": "Added explicit allowance for licensed COVID-19 vaccines."
    },
    {
      "id": "85b6be10-be48-44bc-ac73-9863c52b00eb",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "changeType": "Addition",
      "instanceType": "StudyChange",
      "sectionNumber": "5.10",
      "beforeText": "Not specified",
      "afterText": "Upon study completion, subjects may be enrolled in a pembrolizumab extension study, if available.",
      "summary": "Added language regarding transition to extension studies."
    },
    {
      "id": "a8f8c3de-02d9-43c1-9ba4-3492a7b8677e",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "7.1.1.8",
      "beforeText": "Not specified",
      "afterText": "If subjects are rerandomized, each subject will retain his/her original treatment/randomization number.",
      "summary": "Clarified subject ID retention for extension study enrollment."
    },
    {
      "id": "da5521ae-73de-4183-b0ad-1967f256a9aa",
      "amendmentId": "6aaff637-2d22-4046-8de7-2187f3f2729f",
      "changeType": "Modification",
      "instanceType": "StudyChange",
      "sectionNumber": "Overall",
      "beforeText": "Not specified",
      "afterText": "Minor editorial changes.",
      "summary": "General editorial updates for clarity throughout the document."
    }
  ],
  "computationalExecution": {
    "ready": true,
    "supportedSystems": [
      "EDC",
      "ePRO",
      "CTMS",
      "RTSM"
    ],
    "validationStatus": "complete"
  }
}